At a glance
What is it—and why does it matter?
Semaglutide works as a GLP-1 receptor agonist and increases insulin release after eating. With semaglutide, bigger hsCRP drops were linked to more weight loss, but hsCRP fell before major weight loss (seen by 4 and 8 weeks) and even in people without weight loss. Common Ozempic side effects (more than 1 in 10 people) include diarrhoea, vomiting, and nausea; these are usually mild or moderate and short-lasting.
Each sentence above is copied from a published claim presentation. The links open its evidence record.
Think of Semaglutide as the active molecule. The named products below are specific ways that molecule is formulated, approved, and used. [1]Regulatory labelWegovy prescribing informationCurrent DailyMed label for Wegovy; approved uses, dosing, contraindications, warnings, and adverse reactions.
Simple guide
Semaglutide, in plain English
The main points from the published research. Each one links to the source it comes from.
What it is
A lab-made peptide medicine that copies a natural body signal involved in blood sugar and appetite.
Oral semaglutide was evaluated in the included randomized trials.
Source for this finding
“Nine RCTs (N= 5766; 20-72 weeks) evaluating oral semaglutide, orforglipron, danuglipron, and lotiglipron were included.”
Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.
- Status
- FDA-approved ingredient
- Approved use
- Indications are product-specific. The ingredient should never be treated as one interchangeable dosing record across Ozempic, Wegovy, and Rybelsus.
What the research looks like
Most published findings come from studies in people.
- 471 People 60%
- 76 Animals or lab 10%
- 239 Other or unclear 30%
Counts show where findings come from, not how strong they are. Animal and lab findings are counted together because study types have not been labelled for this profile yet.
What studies in people found
ACP lists semaglutide as a first-line option for weight management in nonpregnant adults with obesity (body mass index ≥30 kg/m2), with moderate-certainty evidence.
Source for this finding
“First-line treatments are semaglutide (moderate-certainty evidence) and tirzepatide (moderate-certainty evidence);”
Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026).At 1 year, sleeve gastrectomy had the highest probability of meeting combined weight and glycaemic targets, followed by tirzepatide and then semaglutide.
Source for this finding
“At 1 year after the index date, sleeve gastrectomy was associated with the highest probability of attaining combined weight and glycaemic targets, followed by tirzepatide and semaglutide.”
1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.The study compared tirzepatide versus injectable semaglutide for preventing MALO in adults with overweight or obesity and type 2 diabetes.
Source for this finding
“This study aimed to compare the effectiveness of tirzepatide versus injectable semaglutide in preventing major adverse liver outcomes (MALO) among adults with overweight or obesity and type 2 diabetes.”
Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.High-dose oral semaglutide reduced percent body weight versus placebo (MD -11.6%).
Source for this finding
“All agents except low-dose (LoD) lotiglipron outperformed placebo in percent body weight reduction; high-dose (HiD) semaglutide (MD -11.6%) and orforglipron (MD -11.8%) showed the greatest effects.”
Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.In this two-center retrospective study of adults with BMI ≥ 35, bariatric surgery was linked to more weight loss than GLP-1RAs like semaglutide for patients eligible for both.
Source for this finding
“In this retrospective two-center study, bariatric surgery was associated with greater weight loss than GLP-1RAs among patients eligible for both options.”
Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery.
What animal and lab studies suggest
Not proven in people. Results in animals or cells often do not hold up in humans.
When comparing semaglutide with tirzepatide and retatrutide, patterns of action differed by drug and model.
Source for this finding
“Integratingin vivoandin vitrodata showed model- and drug-specific patterns of action among the three agents.”
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.The study included pair-fed (PF) controls to help separate drug effects from effects of weight loss and metabolic improvements.
Source for this finding
“we also evaluated pair-fed (PF) controls.”
Beyond weight loss: Disentangling the direct effects of semaglutide vs equivalent calorie restriction on reproductive systems of male and female rats.In B6/ob and DIO mice, CT130 was given biweekly and compared with semaglutide given weekly to evaluate metabolic efficacy.
Source for this finding
“metabolic efficacy was evaluated in B6/ob and DIO mice (CT130 biweekly vs semaglutide weekly).”
A Biweekly GLP-1R Agonist Designed With Drug-Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability.
Safety
Injectable semaglutide labels warn about thyroid C-cell tumors observed in rodents; human relevance is unknown.
Serious risks listed on the product label:
- Acute pancreatitis
- Gallbladder disease
- Acute kidney injury from volume depletion
Do not use OZEMPIC if you have (or your family has) medullary thyroid carcinoma, or if you have MEN 2.
Source for this finding
“OZEMPIC is contraindicated in patients with:•A personal or family history of MTC or in patients with MEN 2[see Warnings and Precautions (5.1)].”
These highlights do not include all the information needed to use OZEMPIC®safely and effectively. See full prescribing information for OZEMPIC.OZEMPIC (semaglutide) injection, for subcutaneous useInitial U.S. Approval: 2017Do not use WEGOVY if a patient has a personal or family history of MTC or has MEN 2.
Source for this finding
“•WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)[see Contraindications (4)].”
These highlights do not include all the information needed to use WEGOVY safely and effectively. See full prescribing information for WEGOVY.WEGOVY (semaglutide) injection, for subcutaneous useInitial U.S. Approval: 2017Do not use RYBELSUS or OZEMPIC tablets if you have a personal or family history of MTC or if you have MEN 2.
Source for this finding
“RYBELSUS and OZEMPIC tablets are contraindicated in patients with:•A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
These highlights do not include all the information needed to use RYBELSUS®andOZEMPIC®tabletssafely and effectively. See full prescribing information for RYBELSUS andOZEMPICtablets.RYBELSUS (semaglutide) tablets, for oral useOZEMPIC (semaglutide) tablets, for oral useInitial U.S. Approval: 2017
How it's used
These describe specific products as labelled or studied. They are not dosing instructions.
Wegovy is injected under the skin once weekly in the belly, thigh, or upper arm.
Source for this finding
“It is injected once a week under the skin in the belly, thigh or upper arm.”
Wegovy | European Medicines Agency (EMA)Inject OZEMPIC under the skin once weekly in the abdomen, thigh, or upper arm.
Source for this finding
“Administer OZEMPIC once weekly, on the same day each week, at any time of the day, with or without meals.•Inject OZEMPIC subcutaneously to the abdomen, thigh, or upper arm.”
These highlights do not include all the information needed to use OZEMPIC®safely and effectively. See full prescribing information for OZEMPIC.OZEMPIC (semaglutide) injection, for subcutaneous useInitial U.S. Approval: 2017“•Administer OZEMPIC once weekly, on the same day each week, at any time of the day, with or without meals.•Inject OZEMPIC subcutaneously in the abdomen, thigh, or upper arm.”
These highlights do not include all the information needed to use OZEMPIC®safely and effectively. See full prescribing information for OZEMPIC.OZEMPIC (semaglutide) injection, for subcutaneous useInitial U.S. Approval: 2017
What we don't know
This profile does not list specific open questions yet.
A missing finding does not mean something is safe or effective.
Identity + structure
A molecule, not a product name.
| Preferred name | Semaglutide | Ingredient |
|---|---|---|
| Pharmacologic class | GLP-1 receptor agonist | Profile record |
| Peptide structure | 31 amino acids | Profile record |
| Also indexed as | semaglutide · GLP-1 analog | Search aliases |
Mechanism + clinical pharmacology
What it does in the body.
Activates GLP-1 receptors, increasing glucose-dependent insulin secretion, reducing glucagon, lowering energy intake through appetite pathways, and delaying early postprandial gastric emptying. [1]Regulatory labelWegovy prescribing informationCurrent DailyMed label for Wegovy; approved uses, dosing, contraindications, warnings, and adverse reactions.
See all 1046 findings and sourcesEvery finding, grouped by topic, with its exact source passages
Evidence ledger
What the evidence says.
These are evidence statements, not individualized medical instructions. Product, dose, population, and study context remain attached to each source.
Study findings
What studies observed in defined populations, comparators, and time periods.
At week 68, 50.5% on semaglutide vs 4.9% on placebo lost at least 15% of body weight.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Average weight loss was 6.7 kg at week 12 and 9.1 kg at week 24.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a 10-year exploratory analysis of people with type 2 diabetes and major depressive disorder, starting semaglutide was linked to lower mortality than starting an SGLT2 inhibitor (RR, 0.55; 95% CI, 0.53-0.56).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The review looked at RCTs and observational studies on semaglutide’s effects on muscle mass, muscle quality, strength, and physical performance.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the overall cohort, median PHQ-9 fell from 10.0 (7.0-14.0) to 6.0 (4.0-8.0).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The main outcome was monthly triptan use measured as DDD per 10,000 people.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Among NAION patients, average estimated cup-to-disc ratio in unaffected fellow eyes was not significantly different for semaglutide users versus other GLP-1 RA users or no GLP-1 RA use.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Adaptive thermogenesis change was not significantly different between semaglutide (delta AT -210.2 kcal/day) and lifestyle (delta AT -373.4 kcal/day).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In ages 18-24, GLP-1 receptor agonist uptake rose from 13 to 686 per 100,000 during 2018-2025.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A pilot program evaluated injectable semaglutide in adults with CFRD.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a high-fat diet induced obesity C57BL/6 mouse model, CHEMBL2108724 reduced body fat content by 25.5 % vs control at 25 nmol/kg sc every two days for 21 days.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Mean baseline body weight was 105 kg (SD 23.8).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By week 68, 50.5% on semaglutide vs 4.9% on placebo lost at least 15% of body weight.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After 12 weeks, semaglutide 1 mg reduced fasting, postprandial, and mean 24-hour glucose versus placebo in patients with type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After six months, HbA1c decreased by 0.51 percentage points on average.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The coprimary endpoints were percent change in bodyweight and the share achieving at least 5% bodyweight reduction.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
At Week 52, MASH resolved without worsening fibrosis in 34.9% with semaglutide plus luseogliflozin vs 19.4% with semaglutide alone.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1-based therapies can lead to clinically meaningful weight loss in people with obesity and chronic pain.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In adults with overweight or obesity without diabetes, subcutaneous semaglutide reduced CRP versus placebo (MD -40.90%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
After one year, the whole study population had 106 new cognitive-impairment cases (43.1 events/100 patients/year).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Handgrip strength did not change significantly after 3 months of semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract says semaglutide’s role in PND remains undefined.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Depressive symptoms were measured with PHQ-9 during routine care before and after starting semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After 12 months of GLP-1RA alone or dual GIP/GLP-1RA therapy, total BMD was preserved in people with obesity and type 1 diabetes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide significantly improved viability and proliferation of NHDFs under diabetic conditions.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Agreement with food-noise statements fell from 47-63% before semaglutide to 15-20% after.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Danish adults using semaglutide for weight management reported a median 6% weight loss after 1-3 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After six months, mean weight decreased by 10.88 kg.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Ozempic is used with diet and exercise to treat adults with type 2 diabetes that is not satisfactorily controlled.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The main outcome was body-weight change from baseline to month 3 for semaglutide versus tirzepatide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this Danish survey, 24% reported reducing or stopping other medicines after starting semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Among 278 patients, HbA1c fell by -0.89% at 6 months and -0.71% at 12 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Appetite and eating behaviors were measured with CoEQ and SNAQ in the semaglutide comparison.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
High-dose semaglutide lowered BMI more than placebo (MD -4.7 kg/m2).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study assessed links between meeting anthropometric targets (or weight change) and normalising outcomes like normoglycemia, blood pressure, triglycerides, and lipids.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After starting semaglutide, liraglutide, dulaglutide, or tirzepatide, 17.2% had a lower recorded background substance count, 38.8% had no change, and 44.0% had a higher count.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In SUSTAIN 6, OZEMPIC (0.5 mg or 1 mg once weekly) vs placebo had a hazard ratio of 0.74 (95% CI: 0.58, 0.95) for time to first MACE over a median 2.1 years.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For achieving ≥10%TBWL, 43% responded with semaglutide versus 70% with ESG (RR 0.62, 95%CI 0.46-0.82, P=0.0009).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In these trials versus placebo, CagriSema reduced body weight in kilograms.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In adults with overweight or obesity without diabetes, subcutaneous semaglutide reduced percent body weight versus placebo (MD -12.04%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
In obese, glucose-intolerant mice treated for 3 weeks, semaglutide alone reduced lean mass.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In BHK cells engineered to express human GLP-1R, semaglutide showed pEC50 11.2 (EC50 = 6.2x10 -12).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At week 68, 69.1% (838) on semaglutide vs 12.0% (69) on placebo lost at least 10% of body weight.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study defined clinically significant depressive symptoms as PHQ-9 ≥ 10.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Structured dietetic care can support assessment, personalised diet changes, GI symptom management, protein optimisation, counselling, physical activity support, and long-term weight maintenance alongside weight-loss drugs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 12 months, body weight decreased by -6.33% (95% CI: -7.92, -4.73; p < 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By week 24, HbA1c decreased by -1.60% with semaglutide 1 mg once weekly (CI, -1.85% to -1.35%).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
By week 68, average body weight changed by -14.9% with semaglutide versus -2.4% with placebo.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Across RCTs in obesity, GLP1-RAs decreased percentage lean mass by -3.06% versus placebo.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a 10-year exploratory analysis of people with type 2 diabetes and bipolar disorder, starting semaglutide was linked to lower mortality than starting an SGLT2 inhibitor (RR, 0.57; 95% CI, 0.51-0.63).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide lowers body weight, with more fat mass lost than lean mass.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Confidence was low before and after the demonstration, with no significant change (2.3 [0.7] vs 1.9 [1.0]; P= .19).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide 7·2 mg reduced bodyweight more than placebo.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In obese, glucose-intolerant mice, semaglutide alone suppressed mitochondrial gene expression in skeletal muscle samples.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At year 1, more people reached HbA1c <7.0% with semaglutide than with alternative treatment.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In a membrane radioligand displacement test (without human serum albumin), semaglutide showed pIC50 9.4 (IC50 = 3.8x10 -10) at the human GLP-1 receptor.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over one year, there were 33 CoI cases with oral semaglutide (26.8 events/100 patients/year) versus 73 with DPP4i (59.3 events/100 patients/year), p<0.0001.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across RCTs in obesity, GLP1-RAs decreased absolute lean mass by -1.74 kg versus placebo.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Having a ΔCAVI of at least 0.2 was not linked to a statistically significant difference in cardiovascular events during follow-up.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
OASIS 1 reported -15.1% body weight reduction with oral semaglutide 50 mg at 68 weeks.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By week 26, semaglutide reduced glycated hemoglobin versus placebo by -0.3 percentage points (least-squares mean difference).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide was associated with a %IOTF30 trajectory reversal of -0.86 percentage points per month (95% CI, -1.06 to -0.66).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Confidence was rated from 1 (no confidence) to 5 (complete confidence).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A survey assessed perceived changes in food noise in US adults using injectable semaglutide for weight management.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the longitudinal survey, IWQOL-Lite-CT composite scores showed internal consistency, test-retest reliability, and construct validity; responsiveness analyses were limited by small weight changes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In mice with LPS-induced inflammatory neurocognitive impairment, semaglutide significantly rescued cognitive deficits and restored hippocampal O-GlcNAcylation.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At baseline, PHQ-9 scores were 0-4 in 53%, 5-9 in 28%, 10-14 in 10%, and ≥15 in 9% of the 354 people with HIV.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Percent body fat decreased significantly after 3 months of oral semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This study tested whether starting GLP-1 drugs (including semaglutide) after an IBS diagnosis was linked to later coded GI symptoms compared with not using GLP-1 therapy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Participants completed 15 of the 34 steps correctly (mean [SD] = 44% [50%]).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In adults with overweight or obesity without diabetes, subcutaneous semaglutide reduced waist circumference versus placebo (MD -9.36 cm).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
The process included 34 steps, worth 1 point each when completed successfully.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The source presents a non-invasive breath test to measure OCTT in mice, with potential translation to clinical studies.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this study of adults with type 2 diabetes who started semaglutide, liraglutide, dulaglutide, or tirzepatide, the median recorded number of background non-GLP-1 glucose-lowering substances increased from 1 to 2, while the median person-level change was 0.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
People with ΔCAVI ≥0.2 did not have a statistically significant difference in cardiovascular events versus those with ΔCAVI <0.2 during follow-up.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the full cohort model, post-Junebot era was linked to higher odds of attrition (OR: 1.178; 95% CI [1.052-1.318]; p = 0.004).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this case series, no one lost weight during pregnancy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The lower MACCE risk with semaglutide was mainly attributed to fewer new heart failure events.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide was associated with a %IOTF30 trajectory reversal of -0.86 percentage points per month (95% CI, -1.06 to -0.66).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In adults with obesity without diabetes, semaglutide 7·2 mg once weekly reduced mean bodyweight more than placebo by week 72.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The analysis identified three themes, including positive and negative experiences of reduced hunger.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In five studies (over 4,000 patients), Ozempic lowered HbA1c by 1.2 to 1.8 percentage points over 10 to 13 months.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Stopping semaglutide for 4 weeks before lipoabdominoplasty was associated with a 10% 30-day complication rate.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Neither semaglutide nor liraglutide caused observable changes in NHEKs.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The main outcome was at least a one-stage fibrosis improvement with no worsening of steatohepatitis at week 52.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
High-dose semaglutide ranked highest for achieving ≥ 10% weight loss.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In FLOW, OZEMPIC reduced the primary composite kidney endpoint versus placebo (HR 0.76; 95% CI 0.66 to 0.88; p=0.0003).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
By Week 24, 96.40% (Test) and 98.80% (Reference) lost at least 5% of weight.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
WtHR increased slightly with lifestyle alone (Δ +0.01) and decreased with semaglutide (Δ -0.04); the adjusted between-group difference was significant (p<0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Ozempic is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
5 cited sources · 5 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
6 cited passages across 5 source records.
Before semaglutide treatment, %IOTF30 increased by 0.29 percentage points per month (95% CI, 0.26, 0.33) in 113 participants.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In SUSTAIN 6, OZEMPIC reduced MACE versus placebo (hazard ratio 0.74; 95% CI 0.58 to 0.95).
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
In REIMAGINE 2, semaglutide 2·4 mg reduced HbA1c by a mean of -1·75 percentage points at week 68.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study aimed to evaluate real-world semaglutide effects on weight and metabolic measures, including 5%, 10% and 15% weight-loss targets at mean 3-month, 6-month and 12-month follow-up.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a study of over 3,000 high-risk diabetes patients, heart attack, stroke, or death happened less often with Ozempic (6.6%) than placebo (8.9%).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Over 12 months, total BMC and BMD did not change.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For all-cause dementia among semaglutide initiators, ≥5% weight-loss responders and non-responders had similar 3-year cumulative incidence (1.54% vs 1.70%; HR 0.87; P=.53).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The conclusion says semaglutide may be considered in ESRD, but results are hypothesis generating and prospective RCTs are urgently needed.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By weeks 40 and 60, appetite outcomes were not significantly different between semaglutide and placebo.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In a 902-person study, after 20 weeks on Wegovy, continuing it led to a further 8% weight loss over 48 more weeks, while switching to placebo led to 7% weight regain.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In adults with type 2 diabetes taking oral semaglutide, mean body weight dropped from 106 kg to 100 kg at 182.5 days and to 98 kg at 365 days (n = 832).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists are not established analgesics.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Compared with lifestyle education alone, lifestyle education plus semaglutide had greater 12-month decreases in body weight, BMI, and waist circumference.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At week 40, weight fell with IcoSema (with semaglutide) but rose with glargine U100 (ETD -4·61 kg; p<0·001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For people with HIV starting semaglutide who had no/minimal depression at baseline, PHQ-9 increased by +1.2 (95% CI 0.5, 1.8).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Structured dietetic care should be a fundamental part of obesity drug treatment, especially as GLP-1 receptor agonists and incretin-based therapies become more common.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In SUSTAIN 6, Ozempic reduced time to first MACE versus placebo (hazard ratio 0.74; 95% CI: 0.58, 0.95).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Among people who started oral semaglutide, 65.8% were still on it at 180 days and 55.2% at 365 days.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The primary endpoints were changes in HbA1c and body weight from baseline to 182.5 and 365 days after starting oral semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a 1,961-person study, average weight loss at 68 weeks was 15% with Wegovy vs 2% with placebo.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For people with HIV with no/minimal baseline depression, PHQ-9 scores increased after starting semaglutide (+1.2; 95% CI 0.5 to 1.8).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study planned to analyze weight-related outcomes by prior liraglutide use, sex, and BMI category.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Danish adults using semaglutide for weight management reported a median 12% weight loss after 3-6 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Ozempic slows (delays) gastric emptying.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Oral semaglutide was associated with lower total energy intake and percent body fat, with no significant change in macronutrient distribution or handgrip strength.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Body weight dropped significantly after 3 months of oral semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After 3 months on oral semaglutide, percent body fat decreased and percent muscle mass increased significantly.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In SUSTAIN 6, OZEMPIC reduced the risk of MACE versus placebo (hazard ratio 0.74; 95% CI 0.58 to 0.95).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study defined poor sleep quality as PSQI > 5.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In SUSTAIN 6, Ozempic reduced MACE vs placebo (hazard ratio 0.74; 95% CI: 0.58, 0.95).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Absolute handgrip strength stayed preserved in both groups, while relative handgrip strength improved with semaglutide (adjusted p=0.003; η²p=0.110).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 40 weeks, HbA1c changed by -1·8 percentage points (SE 0·1) with cagrilintide-semaglutide (2·4 mg each).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In a diet-induced obesity C57BL/6 mouse model, CHEMBL2108724 reduced body weight by 13.4 % vs control at 25 nmol/kg sc every two days for 21 days.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Daily salt intake dropped from 8.9 to 7.0 g/day after 3 months on semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The main outcome was symptomatic remission at 12 weeks (partial Mayo ≤ 2 and rectal bleeding subscore 0).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 12 months, people with psychiatric disorders who started semaglutide had lower cognitive signs/symptoms scores than those on glipizide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 90 days, GLP-1 use was linked to lower rates of chronic diarrhea, constipation, abdominal pain, and bloating/distension versus non-GLP-1 controls (all p < 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide was tested for anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis in HK-2 cells and in mouse UUO and aging models.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For people with HIV with moderately-severe to severe baseline depression, PHQ-9 scores decreased after starting semaglutide (-4.7; 95% CI -7.3 to -2.2).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
High-dose oral semaglutide showed consistent, substantial weight reductions, but comparisons were constrained by low-to-moderate certainty and no head-to-head trials.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 12 months, people with psychiatric disorders who started semaglutide had lower cognitive signs/symptoms scores than those with no antidiabetic treatment.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide was tested for anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis in HK-2 cells and mouse UUO and aging models.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After six months, VAS pain decreased by 2.47 points on average.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Handgrip strength did not change significantly after 3 months on oral semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After 12 weeks at semaglutide 1 mg, fasting glucose and 2-hour post-meal glucose were lower than placebo by 29 mg/dL (22%) and 74 mg/dL (36%), respectively.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
At six months, mean HbA1c decreased by 0.51 percentage points.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this case, the affected eye was short and the fellow eye was highly myopic and longer.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In adults with type 2 diabetes taking oral semaglutide, mean HbA1c fell from 7.9% to 6.8% at 182.5 days and to 6.9% at 365 days (n = 2784).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Among Danish 12–24-year-old GLP-1RA users, only 38% had prescription coverage after 1 year.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After six months, WOMAC total score decreased by 22.50 points on average.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In obese, glucose-intolerant mice, semaglutide alone increased atrophy-related genes in skeletal muscle samples.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Hepatic steatosis, fibrosis, and visceral adiposity indices improved at all follow-up visits.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide can cause substantial weight loss along with reduced lean body mass.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Among lipoabdominoplasty patients, those who continued semaglutide until surgery had a 45% complication rate within 30 days.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
In HFpEF trials, semaglutide increased KCCQ by +8.27 points versus placebo (95% CI 6.04 to 10.50; p <0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a 10-year exploratory analysis of people with type 2 diabetes, starting semaglutide (vs an SGLT2 inhibitor) was linked with lower mortality in bipolar disorder.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At six months, mean VAS pain score decreased by 2.47 points.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The main outcome was percent body-weight change from baseline at weeks 12 and 24.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 12 months, total tissue fat decreased by -1.42% (95% CI: -2.47, -0.36; p = 0.009).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 1 year, semaglutide starters had a larger HbA1c drop than dulaglutide starters (ETD -0.22 percentage points [95% CI -0.30, -0.15]).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 12 months, cognitive signs/symptoms scores were lower with semaglutide but not significantly different from sitagliptin in adults with psychiatric disorders.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 12 months, fat mass decreased by -5.90% (95% CI: -10.50, -1.57; p = 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At week 24, 76.1% reached at least 5% weight loss.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Participants completed 15 of the 34 steps correctly (mean [SD] = 44% [50%]).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Dietitians can help people on GLP-1 receptor agonists or incretin-based therapies maintain nutrition, preserve lean mass, manage GI symptoms, and sustain weight maintenance.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In high-fat diet obese C57BL/6 mice, CHEMBL2108724 (25 nmol/kg SC every two days for 21 days) was reported to reduce body fat content by 25.5 % vs control.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this EHR target-trial emulation, semaglutide users had a lower hazard of first recorded AD diagnosis than matched non-GLP-1 antidiabetic medication users (HR 0.56; N=23,675 per arm; q=0.02).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 12 months, people with psychiatric disorders who started semaglutide had lower cognitive signs/symptoms scores than those on empagliflozin.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In ESRD, pooled weight change with semaglutide was -3.09 kg at 3 months, -3.68 kg at 6 months, and -7.00 kg at 12 months (with reported 95% CIs and I2).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By Week 24, 80.60% (Test) and 80.00% (Reference) lost at least 10% of weight.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At six months, mean WOMAC total decreased by 22.50 points.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Program pauses were linked to higher attrition odds (OR: 2.508; p < 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Over one year, elderly outpatients with HFpEF, obesity, and type 2 diabetes had fewer new cognitive impairment cases with oral semaglutide than with DPP-4 inhibitors (33 vs 73).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide reduced the odds of heart-failure hospitalization versus placebo (odds ratio 0.81; 95% CI 0.75 to 0.88; p <0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Out of 6616 new users, 70.1% stayed on treatment and 29.9% stopped early.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By week 24, HbA1c fell by -1.60% from baseline with 1 mg semaglutide once weekly (CI, -1.85% to -1.35%).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide lowers blood glucose by increasing insulin and decreasing glucagon when glucose is high, and it slightly delays early post-meal stomach emptying.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In Trial 7, semaglutide tablets 14 mg reduced MACE vs placebo (hazard ratio 0.86; 95% CI: 0.77, 0.96) over median follow-up 49.6 months vs 49.4 months.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Energy intake dropped significantly, and macronutrient intake dropped too.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
High-intensity tracking in month 1 (> 25 tracks) predicted attrition (OR: 15.753; p < 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Daily salt intake fell from 8.9 to 7.0 g/day after 3 months of semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The primary outcome was reaching at least 20% weight loss and HbA1c below 5·7% at 1 year.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide lowers blood glucose by increasing insulin and decreasing glucagon when glucose is high.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
No one in the series lost weight during pregnancy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Results support using IWQOL-Lite-CT in observational research as well as clinical trials.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In people with HIV who smoked, starting semaglutide was linked to a mean decrease of 2.5 cigarettes/day, a 24% drop in smoking intensity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In high-fat-diet-induced obese mice, daily oral SGT-M at 5 mg/kg reduced fasting glucose by 65.6%.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study compared total weight loss up to 3 years after treatment using inverse probability weighting and mixed linear models.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At week 44, semaglutide led to greater bodyweight reduction than placebo (estimated treatment difference -9·9 percentage points; 95% CI -11·8 to -8·0; p<0·0001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide plus reduced glargine improved DTSQc scores more than titrated glargine (ETD 2.6; CI95 1.6, 3.5).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide high-dose ranked highest for ≥ 10% weight loss, and semaglutide low-dose ranked highest for ≥ 15% weight loss.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study defined response as a drop of at least 5 PHQ-9 points and at least 3 PSQI points.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Vehicle- and semaglutide-treated mice had similar sucrose concentration-response curves and comparable EC50 values.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In ages 12-17, GLP-1 receptor agonist uptake rose from 1.7 to 72 per 100,000 during 2018-2025.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The coprimary endpoints were percent change in body weight and achieving at least 5% weight reduction.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In ob/ob mice, semaglutide reduced body weight and food intake similarly in males and females.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In 123 people with HIV who smoked, cigarettes/day decreased by -2.5 (95% confidence interval: -3.7 to -1.3) after starting semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 12 months, cognitive signs/symptoms scores were lower with semaglutide than with no antidiabetic treatment in adults with psychiatric disorders.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After starting semaglutide, people with HIV smoked 2.5 fewer cigarettes per day on average (95% CI: -3.7 to -1.3).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this post hoc SELECT analysis, semaglutide was associated with a smaller increase in predicted 20-year dementia risk than placebo (OR 0.91, 95% CI 0.88-0.94) on the dSST.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
People starting with higher CAVI tended to improve less while on oral semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In SUSTAIN 6, Ozempic reduced MACE versus placebo (hazard ratio 0.74; 95% CI: 0.58, 0.95).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Starting semaglutide was linked with fewer incident heart failure events than non-GLP-1RA therapies over up to 2 years (HR 0.69; 95% CI 0.53-0.91).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The share of patients with PHQ-9 ≥ 10 dropped from 55.1% to 11.5% (p < 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At week 40, HbA1c dropped more with IcoSema (with semaglutide) than with glargine U100 (ETD -0·88 percentage points; p<0·001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
At week 68, 69.1% on semaglutide vs 12.0% on placebo lost at least 10% of body weight.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide’s effects on body weight, appetite, and adiposity are described as well established.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Patients had significant weight loss at all follow-up visits.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The simulation’s main outcome for semaglutide timing was time-integrated cycling fibroblast burden (AUC).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In people not eligible for SUSTAIN-7, semaglutide starters lost more weight over 1 year than dulaglutide starters (ETD -2.01 kg [95% CI -3.07, -0.95]).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Waist-to-height ratio rose slightly with lifestyle alone but fell with semaglutide, and the adjusted difference between groups was significant.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 1 year, the adjusted probability of meeting the primary composite outcome was 3·0% (95% CI 2·8-3·2) with semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In adults with obesity without diabetes, semaglutide 7·2 mg once weekly led to a larger mean bodyweight reduction than semaglutide 2·4 mg by week 72.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In the full cohort model (R2= 0.2236), post-Junebot era was linked to higher odds of attrition (OR: 1.178; 95% CI [1.052-1.318]; p = 0.004).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Imaging confirmed NAION and bilateral buried optic disc drusen in this case.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In ob/ob mice, semaglutide minimally affected muscle mass and strength, and females did not lose muscle mass.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide modestly increased total licking and starting trials for sucrose in mice.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By week 68, body weight changed by -15.3 kg with semaglutide vs -2.6 kg with placebo.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After 3 months on semaglutide, people ate significantly less fats and oils, seasonings and spices, and sweets and snacks.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In high-fat-diet-induced obese mice, daily oral SGT-M at 5 mg/kg reduced body weight by 30.3%.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the FLOW trial, Ozempic reduced the primary composite kidney/cardiovascular endpoint vs placebo (HR 0.76; 95% CI 0.66 to 0.88; p=0.0003).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study randomized 573 participants.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema reduced systolic blood pressure.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
SMI-SDS improved more with semaglutide than with lifestyle alone (0.52 vs 0.09; adjusted p<0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 40 weeks, estimated mean HbA1c change was -1·8 (2·4 mg each), -1·5 (1·0 mg each), and -0·1 with placebo.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
HbA1c dropped significantly after 3 months of oral semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists like semaglutide are used to treat Type 2 Diabetes and obesity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this post hoc SELECT analysis, semaglutide was associated with a smaller increase in predicted 5-year dementia risk than placebo (OR 0.74, 95% CI 0.65-0.85) on the dSST.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Among incretin-based therapies, semaglutide has the most direct menopause-specific evidence, but it is limited and mostly observational.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At week 30 in a monotherapy trial, OZEMPIC 0.5 mg once weekly lowered HbA1c versus placebo (difference -1.2; 95% CI -1.5 to -0.9).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
At 6 months, average total body weight loss was 8.67±3.84% with semaglutide versus 12.72±5.67% with ESG (P=0.0001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The review included 11 randomized trials (25,067 participants) comparing semaglutide with placebo or an active control.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Secondary endpoints included changes in LDL-cholesterol, HDL-cholesterol, total cholesterol, triglycerides, HDL/triglycerides ratio, and ALT.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In people not eligible for SUSTAIN-7, semaglutide starters had a larger 1-year HbA1c drop than dulaglutide starters (ETD -0.23 percentage points [95% CI -0.31, -0.15]).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After matching (including GLP-1 RA medications), adolescents and young adults had similar BMI 1 year after surgery.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Among women with prepregnancy overweight or obesity, semaglutide use before and into pregnancy was linked with higher odds of excessive gestational weight gain than no use (aOR=2.88, 95% CI 2.04-4.05).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Percent muscle mass increased significantly after 3 months of oral semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide had higher remission than liraglutide (72.5% vs 60%; OR 1.77, P = .04).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In diabetic rats, semaglutide significantly improved learning and memory, fasting blood glucose, and body weight.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Female rats in both semaglutide and pair-fed groups had increased folliculogenesis.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With semaglutide 2·4 mg, mean HbA1c change was -1·75 percentage points (SE 0·04) at week 68 (efficacy estimand).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Over one year, there were 106 new cognitive impairment cases in the full study population (43.1 events/100 patients/year).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists and dual incretin therapies can produce clinically significant weight loss and improve cardiometabolic outcomes in obesity management.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The main outcome was monthly triptan use in DDD per 10,000 people.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide plus reduced glargine reduced relative daily insulin dose more than titrated glargine (ETD -121.9%; CI95 -143.1, -100.6).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Adjusted for BMI, age, and sex, the survey group had lower baseline IWQOL-Lite-CT scores than STEP 1 by 23.4 (Total), 20.7 (Physical), 20.3 (Physical Function), and 24.8 (Psychosocial) points.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema reduced HbA1c.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a 10-year exploratory analysis of people with type 2 diabetes, starting semaglutide (vs an SGLT2 inhibitor) was linked with lower mortality in major depressive disorder.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After matching, there were 4,668 patients per group in the 30-day cohort and 6,665 per group in the 90-day cohort.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Body composition measures cannot replace directly assessing strength, walking capacity, symptoms, and health status.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At Week 52, ≥ 1-point NAS improvement occurred in 75.5% with semaglutide plus luseogliflozin vs 55.6% with semaglutide alone.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide reduced the narrower secondary kidney composite versus placebo (0·80 [0·69-0·92]).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
STEP UP’s main outcomes included percent bodyweight change and the share of participants losing at least 5% bodyweight with semaglutide 7·2 mg versus placebo from baseline to week 72.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study identified 662,013 GLP-1 RA users, 272,343 bariatric surgery patients, and 158,446 users of other weight-loss medicines.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
More patients achieved the primary composite outcome with semaglutide than with placebo (36% vs. 0%).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this study, using an SGLT-2 inhibitor along with oral semaglutide was linked to larger improvements in CAVI.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide significantly increased viability and proliferation of human dermal fibroblasts under diabetic-like conditions.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
OZEMPIC is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes, and to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In adults with type 1 diabetes and obesity, semaglutide (vs AID use alone) improved achieving a composite of CGM time-in-range targets plus 5% weight loss.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Versus untreated diabetic rats, semaglutide was linked to lower brain MDA, TNF-α, Bax, IL-6, COX-2, and Caspase-3, and higher Bcl-2, catalase, and GSH.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Flexible dosing schedules may help adherence and tolerability without worsening glycemic control, but this is mainly based on indirect evidence and expert opinion rather than direct comparisons.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Weight fell by -3.09 kg at 6 months and -4.77 kg at 12 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In adults with overweight/obesity, semaglutide 2.4 mg led to larger reductions in ad libitum energy intake than placebo at weeks 20, 40, and 60 (291.9 ± 64.4, 240.2 ± 87.8, and 269.5 ± 83.6 kcal less).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Compared with lifestyle alone, semaglutide plus lifestyle had greater 12‑month reductions in weight (Δ -11.0 kg), BMI (Δ -4.0 kg/m²), and waist circumference (Δ -7.0 cm).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In obese C57BL/6 mice, CHEMBL2108724 (25 nmol/kg SC every two days for 21 days) was reported to reduce body weight by 13.4 % vs control.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
From baseline to week 26, semaglutide increased CGM time 70–180 mg/dl vs placebo by 8.8 percentage points (95% CI 3.9 to 13.7).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In these case reports, stopping the GLP-1 receptor agonist led to symptom resolution in all patients.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At Week 52, ≥ 1-stage fibrosis improvement occurred in 26.9% with semaglutide plus luseogliflozin vs 13.9% with semaglutide alone.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The biggest triptan-use reductions were in ages 18-35 (RR 0.86; 0.78-0.94) and in prior users of preventive antimigraine drugs (RR 0.88; 0.82-0.94).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In SUSTAIN 6, OZEMPIC reduced MACE versus placebo (hazard ratio 0.74; 95% CI: 0.58, 0.95).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Ozempic is used with diet and exercise to treat adults whose type 2 diabetes is not satisfactorily controlled.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
There were 143 participants at week 12 and 113 at week 24.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The primary estimand assessed effects regardless of treatment discontinuation or rescue interventions.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide 7·2 mg led to greater mean bodyweight change than semaglutide 2·4 mg.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Epic Cosmos identified 468 712 patients with at least 365 consecutive days of semaglutide or tirzepatide prescriptions.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In adults with type 2 diabetes starting once-weekly subcutaneous semaglutide, body weight decreased at 6 months and at 12 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study included 278 patients.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema reduced waist circumference.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Secondary outcomes included visceral fat, appetite, and metabolic measures when comparing semaglutide and tirzepatide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the overall cohort, median PSQI went from 6.0 (5.0-8.75) down to 3.0 (2.0-4.0).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In people with type 2 diabetes taking oral semaglutide, using an SGLT-2 inhibitor at the same time was linked to more improvement in CAVI.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In women with PCOS, semaglutide was linked to an average weight loss of 7.6-11.5 kg over 3-6 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the meta-analyses, semaglutide probably reduced major adverse cardiovascular events (MACE).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Ozempic is used to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
Before treatment, %IOTF30 increased by 0.29 percentage points per month (95% CI, 0.26, 0.33) in 113 participants.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a 902-person study, after everyone used Wegovy for 20 weeks, over the next 48 weeks people who stayed on Wegovy lost 8% more body weight while those switched to placebo regained 7%.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In mouse lung epithelial cells, semaglutide inhibited hydrogen peroxide-induced senescence in vitro.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Lean mass loss was associated with body weight loss (R2= 0.36, p < 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The primary outcome was time-to-first MALO, a composite of cirrhosis, decompensated events, and hepatocellular carcinoma.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
From baseline to week 68, body weight changed by -15.3 kg with semaglutide vs -2.6 kg with placebo (difference -12.7 kg; 95% CI, -13.7 to -11.7).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In human-derived cells, GLP-1 receptor agonist treatment (such as semaglutide) was linked to better mitochondrial bioenergetics in a meta-analysis (SMD = 1.109).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 68 weeks, semaglutide reduced body weight by -14.9% vs -2.4% with placebo (difference -12.4 percentage points; 95% CI -13.4 to -11.5).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Estimated %IOTF30 reduction at six months was 5.17 percentage points (95% CI, 3.98, 6.36).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a 10-year exploratory analysis of people with type 2 diabetes and schizophrenia, starting semaglutide was linked to lower mortality than starting an SGLT2 inhibitor (RR, 0.67; 95% CI, 0.59-0.75).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The primary endpoint was at least a 1-stage fibrosis improvement with no worsening of metabolic dysfunction-associated steatohepatitis at week 52.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In adults with overweight or obesity, once-weekly subcutaneous semaglutide 2.4 mg improved SF-36v2 Physical Functioning vs placebo by 1.71 points (95% CI 1.07 to 2.35).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In obese adults with type 2 diabetes and rheumatoid arthritis, starting semaglutide was linked with fewer MACCE than starting non-GLP-1RA second-line diabetes therapies over up to 2 years (HR 0.75; 95% CI 0.60-0.94).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the primary outcome analysis, 33 482 (74·3%) patients were treated with semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the meta-analyses, semaglutide probably reduced mortality.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
In this post hoc SELECT analysis, semaglutide lowered the odds of being classified into a higher dementia-risk category by 36% (β -0.44; P< 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After matching, there were 4,668 per group (30-day) and 6,665 per group (90-day).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At year 1, body weight fell more with semaglutide than with alternative treatment.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Across SELECT, FLOW, and SOUL, semaglutide lowered the risk of the primary kidney composite versus placebo (HR 0·84 [95% CI 0·77-0·91]).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Subcutaneous semaglutide is effective for weight reduction in adults with overweight/obesity without type 2 diabetes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
WEGOVY is used (with diet and exercise) to lower the risk of major cardiovascular events in adults with established cardiovascular disease who have obesity or overweight.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In SUSTAIN 6, OZEMPIC (0.5 mg or 1 mg once weekly) reduced MACE versus placebo (hazard ratio 0.74; 95% CI: 0.58, 0.95) over a median of 2.1 years.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Total energy intake fell significantly after 3 months on semaglutide, but macronutrient distribution did not change.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
People ate significantly less fats and oils, seasonings and spices, and sweets and snacks after 3 months of semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema (2·4 mg each) reduced HbA1c more than semaglutide 2·4 mg in this trial population.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The analysis identified three themes: hunger pain from antipsychotics, experiences of reduced hunger, and influences on eating habits.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Estimated %IOTF30 reduction at 12 months was 10.33 percentage points (95% CI, 7.96, 12.71).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Adults with biopsy-confirmed MASH and type 2 diabetes received semaglutide plus luseogliflozin or semaglutide alone at antidiabetic doses for 52 weeks in a randomised open-label trial in Japan.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The share of patients with PSQI > 5 dropped from 55.1% to 16.7% (p < 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The analysis included twelve randomized controlled trials with 6253 adults with type 2 diabetes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 12 months, HbA1c decreased by -0.48% (95% CI: -0.74, -0.22; p < 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At week 68, 19.1% of semaglutide participants reached both BMI < 27 kg/m2 and WHtR < 0.53.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Total calories decreased, but the macronutrient split stayed the same after 3 months of semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In adults with type 2 diabetes starting once-weekly subcutaneous semaglutide, systolic blood pressure decreased at 6 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide has shown significant efficacy in several clinical trials for treating obesity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In adults with type 2 diabetes starting once-weekly subcutaneous semaglutide, HbA1c went down at 6 months and at 12 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide lowered NT-proBNP by a mean difference of -119.7 pg/ml versus placebo (95% CI -144.4 to -95.1; p <0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 1 year, semaglutide starters lost more weight than dulaglutide starters (ETD -1.92 kg [95% CI -2.91, -0.93]).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Bioimpedance showed total body water fell by 1.9 L over 7 weeks, while fat mass was preserved and ECW/TBW stayed stable.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In human aortic endothelial cells under disturbed flow, semaglutide increased ADCY4 expression.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
By week 68, average body weight changed by -14.9% with semaglutide 2.4 mg once weekly vs -2.4% with placebo (difference -12.4 percentage points; 95% CI, -13.4 to -11.5; P < 0.001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
At week 68, 50.5% (612) on semaglutide vs 4.9% (28) on placebo lost at least 15% of body weight.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
At 68 weeks, weight change was -15.3 kg with semaglutide vs -2.6 kg with placebo (difference -12.7 kg; 95% CI -13.7 to -11.7).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In simulations of people with BMI >30 kg/m2 getting Sofwave, starting semaglutide 3 months before Sofwave gave the largest modeled improvement (+0.092 cycling AUC and +41% collagen density).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After 3 months on oral semaglutide, HbA1c and body weight decreased significantly.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study outcomes were new diagnoses of nonscarring alopecia, telogen effluvium, and alopecia areata (negative control).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With semaglutide, bigger hsCRP drops were linked to more weight loss, but hsCRP fell before major weight loss (seen by 4 and 8 weeks) and even in people without weight loss.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Over 12 months, cognitive signs/symptoms scores were lower with semaglutide than with no antidiabetic treatment in adults with psychiatric disorders.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 12 months, mean %TBWL was 10.91±4.66 with semaglutide and 11.92±6.93 with ESG (P=0.41).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is described as a highly effective treatment for obesity and type 2 diabetes.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At week 68, 86.4% on semaglutide vs 31.5% on placebo lost at least 5% of body weight.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Of 42 first-time users followed up, 83% reported still using semaglutide after 6 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Only 38% still had prescription coverage after 1 year.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide’s effects on muscle strength and physical performance vary, especially in older or frail people.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a 10-year exploratory analysis of people with type 2 diabetes, starting semaglutide (vs an SGLT2 inhibitor) was linked with lower mortality in schizophrenia.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 40 weeks, HbA1c changed by -1·5 percentage points (0·1) with cagrilintide-semaglutide (1·0 mg each).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Low-dose semaglutide ranked highest for achieving ≥ 15% weight loss.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In ESRD, pooled HbA1c change with semaglutide was -0.50% at 6 months and -0.75% at 12 months (with reported 95% CIs and I2).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the 1,961-person study, 84% on Wegovy lost at least 5% of body weight vs 31% on placebo.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
CAP decreased by -46.0 ± 14.0 dB/m over 72 weeks with lifestyle plus semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema (2·4 mg each) lowered HbA1c more than semaglutide 2·4 mg at week 68 (difference -0·16 percentage points; p=0·0035).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
At week 44, more participants on semaglutide achieved at least 5% weight loss than on placebo (80·5% vs 24·4%; OR 14·8; p<0·0001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Among semaglutide initiators, weight-loss responders and non-responders had similar 3-year all-cause dementia incidence (1.54% vs. 1.70%; HR 0.87; P= .53).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The analysis suggested attention to patients’ coping styles.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In STEP 9 (n= 407), WOMAC pain score change from baseline at 68 weeks was -41.7 points with semaglutide 2.4 mg versus -27.5 points with placebo.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
People respond differently to GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists, and this variability is a key clinical challenge.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In male ob/ob mice, semaglutide caused only a small loss of skeletal muscle mass.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Six-month adherence was 53.2% post-Junebot vs. 47.3% pre-Junebot (p < 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
In ESRD, pooled BMI change with semaglutide was -1.42 kg/m2 at 3 months, -1.26 kg/m2 at 6 months, and -3.09 kg/m2 at 12 months (with reported 95% CIs and I2).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study examined changes in cigarette smoking among people with HIV who started semaglutide in the CNICS cohort.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide plus reduced glargine led to greater weight reduction than titrated glargine (ETD -8.5 kg; CI95 -9.5, -7.4).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In these trials versus placebo, CagriSema reduced percent body weight.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At six months, mean weight decreased by 10.88 kg.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After 4 weeks, both pair-fed and semaglutide-treated male rats showed improved sperm motility and mucus penetration measures.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across 7 main studies in over 5,500 people with type 2 diabetes, Rybelsus lowered HbA1c by 0.6 to 1.4 percentage points (dose-dependent).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Mean confidence was low before and after the demonstration and was not significantly different (2.3 [0.7] vs 1.9 [1.0]; P= .19).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This systematic review and meta-analysis evaluated GLP1RA-based therapies in people with ESRD (GFR<15 ml/min/1.73 m2 or on renal replacement therapy).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Oral semaglutide 14 mg was linked to more CAVI improvement than 3 mg or 7 mg.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 12 months, lean mass decreased by -1.75% (95% CI: -3.50, -0.48; p = 0.005).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Estimated %IOTF30 reductions were 5.17 percentage points at six months and 10.33 percentage points at 12 months (with 95% CIs).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
From baseline to week 68, mean body weight changed by -14.9% with semaglutide versus -2.4% with placebo (difference -12.4 percentage points; 95% CI, -13.4 to -11.5; P < 0.001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In Study 1, WEGOVY reduced first MACE versus placebo (hazard ratio 0.80 (0.72, 0.90)).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Average weight change was -7.3% at week 12 and -9.9% at week 24.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In Study 1, WEGOVY lowered the risk of first MACE versus placebo (hazard ratio 0.80 (0.72, 0.90)).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
With semaglutide 1 mg once weekly, HbA1c fell by -1.60% at week 24 (CI, -1.85% to -1.35%).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Across RCTs in obesity, GLP1-RAs increased lean mass as a proportion of total weight by 1.81% versus placebo.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For people with HIV starting semaglutide who had moderately-severe to severe depression at baseline, PHQ-9 decreased by -4.7 (95% CI -7.3, -2.2).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Comparative evidence
How the studied intervention compared with another intervention, comparator, or threshold.
ACP lists semaglutide as a first-line option for weight management in nonpregnant adults with obesity (body mass index ≥30 kg/m2), with moderate-certainty evidence.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 1 year, sleeve gastrectomy had the highest probability of meeting combined weight and glycaemic targets, followed by tirzepatide and then semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study compared tirzepatide versus injectable semaglutide for preventing MALO in adults with overweight or obesity and type 2 diabetes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
High-dose oral semaglutide reduced percent body weight versus placebo (MD -11.6%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this two-center retrospective study of adults with BMI ≥ 35, bariatric surgery was linked to more weight loss than GLP-1RAs like semaglutide for patients eligible for both.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In obese adults with type 2 diabetes and rheumatoid arthritis, starting semaglutide was linked to fewer MACCE than starting non-GLP-1RA second-line glucose-lowering therapies, over up to 2 years.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At Week 24, average weight change was -13.8% with Test semaglutide injection and -14.1% with Reference semaglutide injection.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In REIMAGINE 2, CagriSema (2·4 mg each) lowered HbA1c more than semaglutide 2·4 mg at week 68 (difference -0·16 percentage points; 95% CI -0·27 to -0·05; p=0·0035).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The review included 11 randomized trials comparing semaglutide with placebo or an active control (25,067 participants).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
There was no untreated comparison group, so associations were treated as non-causal.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
STEP 12 was a completed phase 3b, randomised, double-blind, placebo-controlled, multicentre, two-armed, parallel-group trial at 19 sites in mainland China and Taiwan.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
STEP UP tested once-weekly subcutaneous semaglutide 7·2 mg versus 2·4 mg and placebo (with lifestyle intervention) for 72 weeks in adults with BMI 30 kg/m2 or greater, without diabetes.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The main comparison was HbA1c change to week 68 for CagriSema (2·4 mg each) versus semaglutide 2·4 mg.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
People with IBS who started a GLP-1 drug within 30 or 90 days were matched to people with IBS who did not get GLP-1 therapy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The review included randomized trials that compared subcutaneous semaglutide with placebo in adults with overweight or obesity without diabetes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The comparison group had no recorded GLP-1 receptor agonist exposure.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a prospective observational study in endometrial cancer patients on fertility-sparing treatment, semaglutide therapy (n= 23) was compared with sleeve gastrectomy (n= 10) and the DEAR lifestyle programme (n= 20) over two years.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study tested whether Intas semaglutide was non-inferior to Innovator semaglutide and evaluated safety in people with T2DM not adequately controlled on metformin.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide therapy was compared with sleeve gastrectomy and the DEAR lifestyle programme in patients with endometrial cancer receiving fertility-sparing treatment.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At week 24, people with baseline IPFD lost less weight (-9.0%) than those without IPFD (-11.6%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study compared CagriSema with semaglutide alone in overweight or obese people.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
When comparing semaglutide with tirzepatide and retatrutide, patterns of action differed by drug and model.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this review, oral semaglutide (any dose) was compared with subcutaneous semaglutide or placebo.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Controls were 1:1 matched UC patients who were not on GLP-1 receptor agonists.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
ACP lists semaglutide as a first-line option (moderate-certainty evidence) for weight management in certain nonpregnant adults with overweight (body mass index ≥27 to 30 kg/m2) and comorbidities.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At week 24, people with type 2 diabetes lost less weight (-7.4%) than those without diabetes (-12.4%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
There are no head-to-head trials of oral vs subcutaneous semaglutide (per this abstract).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Compared with other GLP-1s, semaglutide showed higher odds of other nonscarring alopecia.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
High-dose oral semaglutide reduced percent body weight more than placebo (MD -11.6%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study assigned 100 people to semaglutide 2·4 mg and 100 people to placebo.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A TriNetX-based retrospective target trial emulation analyzed new users of semaglutide versus tirzepatide, with time to first MALO as the main outcome.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Adjusted for BMI, age, and sex, the US longitudinal survey group had lower baseline IWQOL-Lite-CT scores than STEP 1 by 23.4 (Total), 20.7 (Physical), 20.3 (Physical Function), and 24.8 (Psychosocial) points on average.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 40 weeks, HbA1c was lower with cagrilintide-semaglutide (1·0 mg each) than placebo by -1·3 percentage points (-1·8 to -0·9; p<0·0001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This semaglutide cohort study had no untreated comparison group.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The groups were matched for age, BMI, and surgical technique.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 12 months, semaglutide group mean %TBWL was 10.91±4.66, and the between-group difference was not significant (P=0.41).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study included pair-fed (PF) controls to help separate drug effects from effects of weight loss and metabolic improvements.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 6 months, people taking oral semaglutide 14 mg daily lost less total body weight (%) than people who had ESG.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
STEP UP tested once-weekly subcutaneous semaglutide 7·2 mg and 2·4 mg versus placebo (with lifestyle intervention) for 72 weeks in adults with BMI 30 kg/m2or greater, without diabetes.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this study, Intas semaglutide was non-inferior to innovator semaglutide in people with type 2 diabetes not controlled on metformin.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By week 40, bodyweight decreased more with cagrilintide-semaglutide (1·0 mg each) than placebo by -10·4 percentage points (-12·9 to -8·0; p<0·0001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The 6-month %TBWL difference between ESG and semaglutide stayed significant with IPTW (P<0.001) and propensity matching (P=0.021).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
There was no untreated comparison group, so the study treated the findings as non-causal.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
This exploratory analysis used Week 72 data from ESSENCE Part 1, a phase 3 randomized, double-blind, placebo-controlled trial.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
People starting semaglutide had less DMARD escalation than those starting non-GLP-1RA therapies.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For people who did not meet SUSTAIN-7 eligibility, semaglutide users still had bigger 1-year HbA1c and weight reductions than dulaglutide users.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 6 months, oral semaglutide 14 mg daily led to 8.67±3.84% total body weight loss, less than ESG (12.72±5.67%; P=0.0001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across seven RCTs in overweight or obese people, CagriSema led to more weight loss than semaglutide alone (MD = -7.58 kg; 95% CI = -10.30 to -4.86; p < 0.00001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
There are no head-to-head trials of oral vs subcutaneous semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study compared bofanglutide with semaglutide for efficacy and safety.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
At week 24, HbA1c change showed a LSM difference of 0.16 (95% CI: -0.16 to 0.47; P = 0.3266) for Intas semaglutide vs reference, supporting non-inferiority.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 1 year, the adjusted probability of reaching at least 20% bodyweight loss and HbA1c below 5·7% was 3·0% (95% CI 2·8-3·2) for semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
ESSENCE is an ongoing phase 3 trial in people with biopsy-defined metabolic dysfunction-associated steatohepatitis and stage 2 or 3 liver fibrosis, randomized 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 240 weeks.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The analysis included 4942 exposed pregnancies and 5938 unexposed pregnancies (10,880 total).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a 60-wk trial in 120 adults with overweight/obesity, semaglutide 2.4 mg led to larger reductions in ad libitum energy intake than placebo at weeks 20, 40, and 60 (291.9 ± 64.4, 240.2 ± 87.8, and 269.5 ± 83.6 kcal less, respectively).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study compared new users of semaglutide with new users of non-GLP-1RA second-line glucose-lowering therapies.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A study evaluated one-year oral semaglutide versus DPP-4 inhibitors for cognitive-impairment incidence in elderly outpatients with HFpEF, obesity, and type 2 diabetes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By week 40, bodyweight decreased more with cagrilintide-semaglutide (2·4 mg each) than placebo by -12·4 percentage points (95% CI -14·7 to -10·1; p<0·0001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
All-cause death, heart attack, and stroke did not differ significantly between semaglutide and non-GLP-1RA therapies.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At week 40, the combo (with semaglutide) reduced bodyweight more than placebo at both dose levels.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The review uses metabolic and bariatric surgery pathways as a comparison framework to inform obesity pharmacotherapy nutrition care.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In B6/ob and DIO mice, CT130 was given biweekly and compared with semaglutide given weekly to evaluate metabolic efficacy.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In COMBINE 4, adults with type 2 diabetes were randomized to IcoSema (with semaglutide) or once-daily insulin glargine U100.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Over 1 year, semaglutide users had a larger HbA1c drop than dulaglutide users (ETD -0.22 percentage points).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This study compared ESG with oral semaglutide 14 mg in adults with obesity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Compared with placebo and/or lifestyle intervention, semaglutide led to the greatest weight loss in the analyses.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In UK primary-care data, people starting semaglutide had bigger 1-year drops in HbA1c and weight than people starting dulaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study compared lifestyle therapy vs lifestyle plus semaglutide vs bariatric surgery for non-invasive liver steatosis and fibrosis markers.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The review analyzed phase 3 RCTs in adults (BMI ≥ 25 kg/m²) lasting ≥ 52 weeks that compared semaglutide at approved weight-management doses versus placebo or other drugs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
At 40 weeks, HbA1c was lower with cagrilintide-semaglutide (2·4 mg each) than placebo by -1·7 percentage points (95% CI -2·0 to -1·3; p<0·0001).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Bariatric-surgery nutrition principles need adapting for GLP-1 receptor agonist care, but can help integrate dietitians into obesity pharmacotherapy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide had higher remission rates than liraglutide (72.5% vs 60%; OR 1.77, P = .04).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study compared tirzepatide versus injectable semaglutide for preventing MALO in adults with overweight/obesity and type 2 diabetes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The groups were matched 1-to-1 using demographics, comorbidities, medications, and metabolic variables (including NIH Stroke Scale scores, Hemoglobin A1c, and BMI).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In SEPRA, 644 participants were randomized to semaglutide and 634 to alternative treatment.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In early-stage type 2 diabetes, the combo (with semaglutide) lowered HbA1c more than placebo at both dose levels.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Randomized trials in this review assessed CagriSema versus placebo.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After adjustment, ESG still exceeded semaglutide for 6-month %TBWL by an adjusted mean difference of 4.04% (P=0.0001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Some eligible RCTs compared CagriSema with placebo.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Compared with sitagliptin, semaglutide had lower 12-month cognitive signs/symptoms scores, but the difference was not statistically significant.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Compared with placebo at 40 weeks, HbA1c was lower by -1·7 (2·4 mg each) and -1·3 (1·0 mg each).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this study, 4-week semaglutide discontinuation and semaglutide-naïve controls both had a 10% 30-day complication rate after lipoabdominoplasty.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Weight loss percent and whether patients used semaglutide vs tirzepatide were not linked to response in the multivariable models.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A higher recorded background substance count was most common with dulaglutide (52.9%) and least common with tirzepatide (20.4%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 12 months, %TBWL was 10.91±4.66 with semaglutide vs 11.92±6.93 with ESG (P=0.41).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Intas semaglutide (test) was compared for non-inferiority versus Innovator semaglutide (reference) in adults (18-65 years) with type 2 diabetes inadequately controlled on metformin (≥1500 mg/day) and baseline HbA1c ≥7%-<10.5%.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study aimed to compare 1-year weight, blood-sugar, and selected safety outcomes for semaglutide vs tirzepatide vs sleeve gastrectomy in adults with obesity and type 2 diabetes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In adults with obesity without T2DM, the composite cardiovascular outcome occurred less often with metabolic/bariatric surgery than with semaglutide therapy (4.4% vs 6.6%; HR 0.402).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Mechanism
Source-backed statements about targets, pathways, and biological response.
Weight loss associated with semaglutide-like GLP-1 therapy is described as potentially slowing the normal adolescent gain of muscle and bone mass.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The review identified 1547 records, screened 1203 after removing duplicates, included 17 studies, and pooled 11 in the quantitative analysis.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Ac-semaglutide prolongs cAMP signaling.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
IDE breaking down GLP-1 (but not insulin) is described as a major way glucose control is regulated.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide increases insulin release after food, helping control blood sugar.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In a bleomycin mouse model, semaglutide’s key targets were explored using HSF1 shRNA or a Sirt1 inhibitor.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In mice, semaglutide alone suppressed mitochondrial gene expression in skeletal muscle samples.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study tested semaglutide’s effects on pulmonary fibrosis and how it might work.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The paper notes that pre-surgery GLP-1 receptor agonist use can confound comparisons of sleeve gastrectomy outcomes in younger patients.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide promotes weight loss by reducing appetite, delaying gastric emptying, and decreasing energy intake.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
OWLiver® metabolomics algorithms can stage MASLD severity without a liver biopsy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In vitro, mouse lung epithelial cells were made senescent with hydrogen peroxide and treated with semaglutide.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This paper is a narrative review about structured dietetic care for adults using GLP-1 receptor agonists or related incretin-based therapies for weight management.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the UUO model, semaglutide’s effects were linked to PI3K-AKT inhibition.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
“Hunger pain” meant extreme hunger, never feeling full, and constant thoughts about food.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide promotes weight loss by reducing appetite, delaying gastric emptying, and decreasing energy intake.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Ketone ester co-treatment prevented semaglutide-related changes in mitochondrial and atrophy-related gene expression.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Acetylated semaglutide (Ac-semaglutide) shows altered GLP1R trafficking.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study uses the term "hunger pain" for extreme hunger with no satiety and constant thoughts about food.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study compared semaglutide plus reduced insulin glargine vs titrated insulin glargine for HbA1c, weight, insulin dose, and satisfaction.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a peptide that activates the GLP-1 receptor.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By 2025, increasing GLP-1 receptor agonist use was driven by semaglutide for weight management.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study focused on starting a GLP-1 receptor agonist or a dual GIP/GLP-1 receptor agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The authors conclude that teens have more pre-surgery GLP-1 receptor agonist exposure and that studies should control for it.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In BHK cells expressing human GLP1 receptor, CHEMBL2108724 activated a CRE-luciferase reporter with EC50 = 0.0062 nM (3 hrs, no human serum albumin).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists are not presented as substitutes for tolvaptan’s mechanism in ADPKD.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the aging model, semaglutide was linked to reducing G2/M arrest.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Researchers optimized a mild, light-driven method that uses sulfinate salts to make carbon-centered radicals and couple them to cystine disulfide bonds in peptides.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The main outcomes were 1-year HbA1c and weight change, analyzed using a new-user active-comparator cohort approach with marginal structural models and inverse probability weighting.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The simulations say GLP-1RA therapy dynamically and unevenly changes tissue mechanosensitivity that affects Sofwave remodeling.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study calculated adaptive thermogenesis by comparing measured and predicted resting energy expenditure at baseline and 12 months, and also ran a sensitivity analysis using the Ostendorf equation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The main outcome was body-weight change from baseline to month 3.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The review discusses evidence that GLP-1 receptor agonists may overcome vascular regenerative cell exhaustion, which involves loss of bone marrow-derived progenitor cells needed for vessel repair.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
The matching process included GLP-1 receptor agonist medications among the pre-surgery characteristics.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Oral semaglutide has about ~1% bioavailability and requires SNAC to help absorption.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
New outcome events were evaluated using risk ratios, Kaplan–Meier hazard ratios, and log-rank tests.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The paper considers GLP-1 receptor agonists as metabolic candidates to test for modifying ADPKD progression.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists engage pathways implicated in mitochondrial biogenesis, dynamics, and mitophagy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The search covered multiple sources from inception to January 2026.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide activated the human GLP1 receptor in BHK cells (3 hrs, no human serum albumin) with EC50 = 0.0062 nM in a CRE luciferase assay.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists are described as affecting gut motility and visceral sensitivity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Ac-semaglutide changes GLP1R trafficking, reduces β-arrestin recruitment, and prolongs cAMP signaling.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP1R agonists can signal through both G protein and β-arrestin pathways, which are linked to different receptor shapes and trafficking behaviors.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the reported case, bone marrow showed preserved cellularity and granulocyte maturation arrest at the promyelocyte/myelocyte stage.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Simulations and MM-GBSA predicted favorable interaction patterns for the representative analogues.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This paper is a narrative review that searched PubMed up to 25 May 2026 for human studies (2005-2026) on predictors of different responses to these therapies.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study outcomes included coded chronic diarrhea, constipation, abdominal pain, malabsorption, and bloating/distension.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Diet was measured by a food frequency questionnaire and body composition by bioelectrical impedance.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the simulations, when semaglutide was started 3 months before Sofwave, it gave the biggest improvement in cycling fibroblast AUC and collagen density (non-monotonic timing effect).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists have anti-inflammatory and antioxidant properties.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Her bone marrow showed preserved cellularity and granulocyte maturation arrest at the promyelocyte/myelocyte stage.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In mice, bleomycin lung fibrosis was treated with semaglutide, and HSF1 or Sirt1 were manipulated to study targets.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study investigates spray-drying microencapsulation of semaglutide using water-soluble polymers (including PVP) plus trehalose.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists commonly cause nausea and vomiting.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In BHK cells, CHEMBL2108724 activated the human GLP1 receptor with EC50 = 0.0062 nM (3 hrs, no human serum albumin).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The model included semaglutide as one of the obesity treatment strategies.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The outcomes included membrane potential, bioenergetics measures (like ATP-linked oxygen use and ATP production), and mitochondrial reactive oxygen species.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A short semaglutide-derived segment that engages GLP-1R was used to build new scaffolds.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this model, LPS inhibited AKT O-GlcNAc modification and AKT-mTOR activity, increased mTOR–gephyrin binding, disrupted GABAAR distribution, worsened neuronal apoptosis, and impaired synaptic plasticity.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Exercise is described as possibly working together with semaglutide-like GLP-1 metabolic improvements to enhance functional outcomes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The survey asked 22 multiple choice questions and included the five-item Food Noise Questionnaire (FNQ).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP1R agonists can signal through both G protein and β-arrestin pathways.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Simulations and MM-GBSA suggested the representative analogues can adopt receptor-compatible poses.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide reversed LPS-related abnormalities by increasing AKT O-GlcNAcylation, activating AKT-mTOR signaling, promoting mTOR–gephyrin dissociation, restoring synaptic GABAAR localization, reducing neuronal damage, and rescuing synaptic plasticity.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonist use before surgery may confound comparisons between adolescents and young adults undergoing sleeve gastrectomy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This was a 40-week, phase 3b, open-label randomized study with 1:1 assignment to semaglutide plus reduced glargine or titrated glargine.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study included a semaglutide-user group when comparing unaffected fellow eyes of NAION patients.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Na+ is described as only screening electrostatically, with no binding term needed to explain the data.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Future research should test how to deliver dietetic care with incretin-based therapies and how to identify who needs more intensive support.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The analysis looked at all IBS patients and also separately at IBS-D (K58.0) and IBS-C (K58.1).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
LPS reduced AKT O-GlcNAc modification and AKT-mTOR pathway activity in this model.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide increases insulin release from the pancreas after food.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
ΔCAVI was calculated as baseline CAVI minus follow-up CAVI; if ΔCAVI was positive, arterial stiffness improved.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In vitro, semaglutide anti-senescence targets were screened by transcriptomics, and HSF1 genes were silenced with siRNA.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In female mice, AgRP neuron activation is required for the full weight-lowering effects of GLP-1 receptor agonists.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the model, the 3-month semaglutide benefit came from direct fibroblast priming (+0.118 AUC) offset by adipose support loss (-0.026 AUC).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
The study used propensity score matching to balance baseline covariates between tirzepatide and semaglutide users.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a cell assay without human serum albumin, CHEMBL2108724 displaced radiolabeled GLP1 from the human GLP1 receptor with IC50 = 0.13 nM.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study tracked diet and body changes over 24 weeks during GLP-1 receptor agonist obesity treatment in a real-world clinic.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
CHEMBL2108724 bound the human GLP1 receptor in BHK cells (2 hrs, no human serum albumin) with IC50 = 0.13 nM in a displacement assay.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Behavioral, biochemical, and immunofluorescence assays were used to evaluate cognition and molecular changes.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide was treated as a GLP-1 receptor agonist in this study.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The review included RCTs, observational studies, large database analyses, and pharmacovigilance disproportionality studies in semaglutide recipients.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The analysis suggested attention to patients’ coping styles.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In HEK293 cells expressing human GLP-1 receptor, semaglutide had EC50 = 0.052 nM for cAMP response at 60 mins (HTRF assay).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a GLP-1–like drug (94% similar to human GLP-1) that activates the GLP-1 receptor.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide 2·4 mg is a GLP-1 receptor agonist.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide lowers blood glucose by increasing insulin and lowering glucagon when glucose is high, and it slightly delays early after-meal gastric emptying.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In the case, bone marrow testing showed preserved cellularity with granulocytic maturation arrest at the promyelocyte/myelocyte stage.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In mice, semaglutide alone increased atrophy-related genes in skeletal muscle samples.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study analyzed outcomes at 2-4 months, 5-8 months, and 9-15 months of follow-up.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide was studied as an oral GLP-1 receptor agonist for weight management in adults with overweight/obesity without diabetes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide lowers blood glucose by increasing insulin and decreasing glucagon when glucose is high, and it slightly delays early post-meal stomach emptying.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
GLP-1 receptor agonists like semaglutide mainly work by improving blood sugar control, reducing appetite, slowing stomach emptying, and causing weight loss.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study used linear mixed models to estimate PHQ-9 changes after semaglutide, overall and by baseline depression severity, BMI, diabetes, and antidepressant use.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study looked at links between starting GLP-1 drugs and later GI outcomes in people with IBS using EHR data.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Most cysteine peptide modifications use the thiol as a nucleophile, but an umpolung approach instead uses the cystine disulfide as an electrophile.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study tested whether early eGFR changes explain (mediate) any link between dapagliflozin plus semaglutide and HF/MI-related outcomes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide works as a GLP-1 receptor agonist and increases insulin release after eating.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study used medication dates to label substances as baseline (before index) or later (on/after index) and categorized each patient’s change as lower, unchanged, or higher.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Metabolic and bariatric surgery pathways show dietitians’ roles before, during, and after major weight-loss interventions, including assessment, supplement guidance, diet progression, lab monitoring, and long-term maintenance.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The scaffolds were stabilized using lactam stapling and bulky aromatic non-natural amino acids.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists affect pathways involved in making new mitochondria, mitochondrial shape/behavior, and mitochondrial recycling.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide acts like GLP-1, boosting insulin release after meals to help control blood sugar.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The study established an LPS-induced inflammatory neurocognitive impairment mouse model via intracerebroventricular injection.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The interviews were analysed using Braun & Clarke's reflexive thematic analysis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
How much AgRP neurons are required for GLP-1 receptor agonists’ weight-lowering effects varies by sex, diet, and how AgRP is disrupted.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide lowers blood glucose by increasing insulin and decreasing glucagon when blood glucose is high.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide-loaded InStrips were made using electrospinning.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide mainly works via systemic metabolic unloading by reducing energy intake, body weight, insulin resistance, and adipose-liver substrate flux.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Ac-semaglutide reduces β-arrestin recruitment.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide and liraglutide were tested in human dermal fibroblasts and keratinocytes under diabetes-like conditions for oxidative stress and wound healing.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Researchers created an LPS-induced inflammatory neurocognitive impairment mouse model using intracerebroventricular injection.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study was a retrospective target trial emulation using TriNetX, analyzing new users of tirzepatide and semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In HEK293 cells expressing human GLP-1 receptor, CHEMBL2108724 had EC50 = 0.052 nM for cAMP response at 60 mins (HTRF assay).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Gdn+ binding reduces net charge and dramatically destabilizes GLP-1 analogs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study tested whether adding an SGLT2 inhibitor to a GLP-1 receptor agonist could improve liver histology in adults with biopsy-proven MASH and type 2 diabetes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The results outline a practical way to build stabilized semaglutide-derived peptide scaffolds.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The interviews were analysed with Braun & Clarke’s reflexive thematic analysis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The authors say this is the first systematic review and meta-analysis on GLP-1 receptor agonists’ direct mitochondrial effects in human-derived lab cell models.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With 2% human serum albumin present, semaglutide’s displacement IC50 at the human GLP1 receptor in BHK cells was 357.0 nM (2 hrs).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The authors conducted a network meta-analysis comparing different doses, durations, and interventions in type 2 diabetes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study tested spray-dried microencapsulation of semaglutide using water-soluble polymers (including PVP) plus trehalose.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide lowers blood sugar by increasing insulin and decreasing glucagon when glucose is high.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Many metabolite-level mechanisms are still not fully defined in human MASH.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This was a single-center retrospective observational cohort study that included semaglutide treatment.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A retrospective observational study described real-world semaglutide use in primary care, including titration, discontinuation, and weight change in adults with overweight or obesity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This was a prospective, randomized, open-label, multicenter phase 3 trial run from July 2025 to February 2026.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 is rapidly broken down by circulating proteases like DPP-4.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study measured change using %IOTF30, which is BMI as a percent of the age- and sex-specific IOTF obesity threshold.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Pharmacokinetics
How the studied compound is absorbed, distributed, metabolized, and cleared.
Semaglutide has an absolute bioavailability of 89%.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
5 cited passages across 3 source records.
Subcutaneous semaglutide has ~89% bioavailability.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide’s half-life is about one week, and it can stay in the blood for about five weeks after the last tablet dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Mean follow-up was 39·5-47·5 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide has 89% absolute bioavailability, and peak levels occur 1 to 3 days after a dose.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
Semaglutide is >99% bound to plasma albumin.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In mini-pigs given semaglutide i.v., the plasma half-life is ~46 hours.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Outcomes were analyzed at 2-4 months (T1), 5-8 months (T2), and 9-15 months (T3).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide’s half-life is about 1 week, and it can remain in the body for about 5 weeks after the last dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide has an elimination half-life of about 1 week and can remain in the blood for about 5 weeks after the last dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide’s half-life is about 1 week, and it can remain in the body for about 5 weeks after the last dose.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Semaglutide’s half-life is about one week in people with type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide has 89% absolute bioavailability, and peak concentration occurs 1 to 3 days after a dose.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
In Gottingen mini pig, CHEMBL2108724 had reported bioavailability of 94.0 % after 2 nmol/kg subcutaneous dosing.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide has a half-life of about 1 week and can remain in the body about 5 to 7 weeks after the last 2.4 mg dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide’s half-life is about one week in patients with type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
These semaglutide tablets include SNAC to help absorption, which mainly happens in the stomach.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
CT130’s half-life was 13.9 h and was reported as 1.4-fold versus semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide has an elimination half-life of approximately 1 week and can remain in circulation for about 5 to 7 weeks after the last 2.4 mg dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide’s half-life is about 1 week and it can remain in circulation for about 5 weeks after the last dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide’s half-life is about 1 week, and it can remain in the body for about 5 weeks after the last dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide has a very long blood half-life (168 h).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Safety findings
Observed or labeled risks, adverse effects, and safety signals.
Common side effects (more than 1 in 10 people) include diarrhoea, vomiting, and nausea; these are mild or moderate and short-lasting.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Common Ozempic side effects include diarrhoea, vomiting, and nausea; these are usually mild or moderate and short-lasting.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
It is not known whether WEGOVY causes thyroid C-cell tumors (including MTC) in people.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rodents, semaglutide caused thyroid C-cell tumors; it’s unknown if this happens in humans with RYBELSUS or OZEMPIC tablets.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rodents, semaglutide caused thyroid C-cell tumors, but it is unknown whether OZEMPIC causes these tumors in humans.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rodents, semaglutide caused thyroid C-cell tumors, but it is unknown if OZEMPIC causes these tumors in humans.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In a thorough QTc trial, semaglutide did not prolong QTc intervals at doses up to 1.5 mg at steady-state.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In glycemic control trials, 32 (1.0%) OZEMPIC-treated patients developed anti-semaglutide antibodies.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Across certain clinical trials, 14/2,924 (0.5%) semaglutide tablet-treated patients developed anti-semaglutide antibodies; 7 (0.2%) cross-reacted with native GLP-1.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Common Ozempic side effects (more than 1 in 10 people) include diarrhoea, vomiting, and nausea; these are usually mild or moderate and short-lasting.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rodents, semaglutide caused dose- and duration-dependent thyroid C-cell tumors at clinically relevant exposures, and it is unknown if Ozempic causes these tumors in humans.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In a thorough QTc trial, semaglutide did not prolong QTc at doses up to 1.5 mg at steady state.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rodents, semaglutide caused thyroid C-cell tumors; it’s unknown if this happens in humans.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Rybelsus could worsen diabetic retinopathy in some patients.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In trials, 14/2,924 (0.5%) developed anti-semaglutide antibodies, with no clinically significant effect on semaglutide tablet pharmacokinetics identified.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Rybelsus may worsen diabetic retinopathy in some patients, so those patients will be monitored carefully.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
It is not known whether RYBELSUS and OZEMPIC tablets cause thyroid C-cell tumors (including MTC) in humans.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide (Ozempic) can cause serious worsening of diabetic retinopathy; it may affect up to 1 in 10 people.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rodents, semaglutide caused thyroid C-cell tumors; whether this happens in humans is unknown.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rodents, semaglutide causes thyroid C-cell tumors in a dose- and duration-dependent way at clinically relevant exposures; whether this happens in humans is unknown.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rodents, semaglutide caused thyroid C-cell tumors; it is unknown whether OZEMPIC causes these tumors in humans.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rodents, semaglutide caused thyroid C-cell tumors, but it is unknown whether this happens in humans.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In trials, 32 (1.0%) OZEMPIC-treated patients developed anti-semaglutide antibodies; 19 (0.6%) had antibodies that cross-reacted with native GLP-1, and neutralizing activity was uncertain.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rodents, semaglutide caused thyroid C-cell tumors; it is unknown if OZEMPIC causes these tumors in humans.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rodents, semaglutide caused thyroid C-cell tumors, and risk increased with higher dose and longer treatment duration, at clinically relevant exposures.
3 cited sources · 3 regulatory records
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
In rodents, semaglutide caused thyroid C-cell tumors; it is not known if OZEMPIC causes these tumors in humans.
1 cited source · 1 regulatory record
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In a 2-year trial, diabetic retinopathy complications occurred in 3.0% with OZEMPIC vs 1.8% with placebo.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Contraindications
Circumstances in which a specific product label says it should not be used.
Do not use OZEMPIC if you have (or your family has) medullary thyroid carcinoma, or if you have MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use WEGOVY if a patient has a personal or family history of MTC or has MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use OZEMPIC if you or your family have had medullary thyroid carcinoma (MTC), or if you have MEN 2.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Do not use OZEMPIC if you or your family have had MTC, or if you have MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use RYBELSUS or OZEMPIC tablets if you have a personal or family history of MTC or if you have MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use RYBELSUS or OZEMPIC tablets if you have a personal or family history of MTC or if you have MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use OZEMPIC in people with a personal or family history of MTC or with MEN 2.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
For adolescents, stop and re-check treatment if BMI hasn’t fallen by at least 5% after 12 weeks on 2.4 mg (or the maximum tolerated dose).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use semaglutide tablets in people with a personal or family history of MTC or with MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use OZEMPIC if the patient is hypersensitive to semaglutide or any product component.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use WEGOVY if there is a personal or family history of MTC or if the patient has MEN 2.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Do not use OZEMPIC if there is a personal or family history of MTC, or if the patient has MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use OZEMPIC if you have a personal or family history of MTC, or if you have MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use OZEMPIC if you have a personal or family history of MTC or if you have MEN 2.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 2 source records.
Do not use RYBELSUS or OZEMPIC tablets in people with a personal or family history of MTC or with MEN 2.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use Ozempic if you have a personal or family history of medullary thyroid carcinoma (MTC) or have MEN 2.
7 cited sources · 7 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
11 cited passages across 7 source records.
Do not use OZEMPIC if you have a personal or family history of MTC or if you have MEN 2.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Interactions
Source-backed product and drug interaction statements.
When taken with semaglutide tablets, levothyroxine exposure increased by 33% (90% CI: 1.25 to 1.42).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use WEGOVY together with other semaglutide products or other GLP-1 receptor agonists.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Taking levothyroxine with semaglutide tablets increased levothyroxine exposure by 33% (90% CI: 1.25 to 1.42).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
OZEMPIC delays gastric emptying and could affect absorption of oral medicines, though trials found no clinically relevant effect on absorption.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Low blood sugar risk is higher when OZEMPIC is used with sulfonylureas or insulin, so the other drug’s dose may need to be lowered.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Using WEGOVY with other semaglutide products or other GLP-1 receptor agonists is not recommended.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Regulatory status
Product-, indication-, and jurisdiction-specific regulatory records.
RYBELSUS and OZEMPIC tablets are used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Wegovy received EU-wide marketing authorisation on 6 January 2022.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
WEGOVY is indicated (with reduced calories and more physical activity) to reduce major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Ozempic (semaglutide) received EU-wide marketing authorisation on 8 February 2018.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
OZEMPIC is used to lower the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Wegovy is under additional monitoring.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Wegovy was granted EU-wide marketing authorisation on 6 January 2022.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
WEGOVY is indicated (with diet and activity changes) to reduce major cardiovascular events in adults with established cardiovascular disease who have obesity or overweight.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
RYBELSUS and OZEMPIC tablets are indicated to reduce the risk of major cardiovascular events in high-risk adults with type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
RYBELSUS and OZEMPIC tablets are indicated to improve glycemic control in adults with type 2 diabetes, along with diet and exercise.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
OZEMPIC is indicated to lower the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
OZEMPIC is indicated to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide tablets are indicated to improve glycemic control in adults with type 2 diabetes and to reduce major cardiovascular event risk in high-risk adults with type 2 diabetes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
WEGOVY is indicated (with diet and activity changes) for long-term weight reduction and maintenance in adults and ages 12+ with obesity, and in adults with overweight plus at least one weight-related condition.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
RYBELSUS and OZEMPIC tablets are used in adults with type 2 diabetes to improve glycemic control and to reduce major cardiovascular event risk in high-risk adults.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration
Product-specific route, timing, formulation, and use instructions—not universal dosing advice.
Wegovy is injected under the skin once weekly in the belly, thigh, or upper arm.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Wegovy comes in pre-filled injection pens and is injected under the skin once a week in the belly, thigh, or upper arm.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Inject OZEMPIC under the skin once weekly in the abdomen, thigh, or upper arm.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
Inject OZEMPIC under the skin in the abdomen, thigh, or upper arm.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
WEGOVY is taken once weekly on the same day each week, any time of day, with or without meals.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
RYBELSUS and OZEMPIC tablets are not interchangeable milligram-for-milligram.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Ozempic is a prescription-only solution for injection in prefilled pens.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 1 source record.
Inject OZEMPIC under the skin of the abdomen, thigh, or upper arm, and rotate injection sites weekly within the same body region.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Rybelsus is taken by mouth as a tablet once a day.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Take 1 tablet in the morning on an empty stomach with up to 4 ounces of water, then wait at least 30 minutes before eating, drinking, or other oral medicines.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Rybelsus is taken by mouth as a tablet once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject OZEMPIC under the skin in the abdomen, thigh, or upper arm, and rotate sites weekly within the same region.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Rybelsus is a tablet taken by mouth once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Take Ozempic once weekly on the same day each week, any time of day, with or without food.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 2 source records.
Wegovy comes as a pre-filled injection pen and is injected under the skin once a week (belly, thigh, or upper arm).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject WEGOVY under the skin once weekly (same day each week), any time of day, with or without meals, in the abdomen, thigh, or upper arm.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Participants will fill out a questionnaire on how they take their Rybelsus® tablets during a regular doctor visit.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Inject OZEMPIC under the skin in the abdomen, thigh, or upper arm, and rotate injection sites each week.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Dose records
Product- and indication-specific dose statements preserved separately to prevent unsafe generalization.
Adults start WEGOVY at 0.25 mg under the skin once weekly.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
OZEMPIC dosing starts at 0.25 mg weekly for 4 weeks, then 0.5 mg weekly; it can be increased to 1 mg weekly and then 2 mg weekly if needed. Max is 2 mg weekly.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The starting dose is 0.25 mg once a week.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Start 0.25 mg under the skin once weekly for 4 weeks, then 0.5 mg once weekly; if needed after at least 4 weeks on 0.5 mg, increase to 1 mg once weekly (max 1 mg once weekly).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For ages 12+ with obesity: maintenance is 2.4 mg once weekly; if not tolerated, reduce to 1.7 mg once weekly, and stop if 1.7 mg isn’t tolerated.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adults start WEGOVY at 0.25 mg once weekly by subcutaneous injection, then increase to a maintenance dose of 1.7 mg or 2.4 mg once weekly.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If you miss a dose: take it ASAP if the next dose is more than 48 hours away; otherwise skip it and take the next dose on the usual day.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Wegovy’s weekly dose is gradually increased over 16 weeks to reduce the risk of gut symptoms.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Start OZEMPIC at 0.25 mg once weekly for 4 weeks; this starting dose is for initiation and does not control blood sugar.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Start OZEMPIC at 0.25 mg under the skin once weekly for 4 weeks.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
The maximum recommended Ozempic dose is 2 mg once weekly.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Adults start WEGOVY at 0.25 mg subcutaneously once weekly.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
RYBELSUS starts at 3 mg once daily for Days 1 to 30, and that dose is not effective for glycemic control.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The maximum recommended OZEMPIC dose is 1 mg once weekly.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The maximum recommended Ozempic dose is 2 mg once weekly.
4 cited sources · 4 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
6 cited passages across 4 source records.
Start OZEMPIC at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly; it can be increased to 1 mg and then 2 mg once weekly (max 2 mg once weekly) after at least 4 weeks at each step.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Ozempic starts at 0.25 mg once weekly, increases after four weeks to 0.5 mg, and can be increased up to 1 mg once weekly if needed.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For patients aged 12 years and older, the maintenance dose is 2.4 mg once weekly.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After four weeks, the dose should be increased to 0.5 mg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Start at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly; if needed, increase to 1 mg once weekly (max 1 mg weekly).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Start at 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The maximum recommended dose is 2 mg once weekly.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If needed after at least 4 weeks on 0.5 mg weekly, OZEMPIC can be increased to 1 mg weekly, which is the maximum recommended dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Adult maintenance dosing is 2.4 mg (recommended) or 1.7 mg once weekly.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
If needed, the dose can be increased up to a maximum of 1 mg once a week.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Start OZEMPIC at 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 2 source records.
Start at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly; if needed after at least 4 weeks, increase to 1 mg once weekly (max 1 mg weekly).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
If needed for more blood sugar control, OZEMPIC can be increased up to 2 mg once weekly, after at least 4 weeks on 0.5 mg and at least 4 weeks on 1 mg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Start at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly; if needed, increase to 1 mg once weekly (max 1 mg weekly).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Start OZEMPIC at 0.25 mg once weekly for 4 weeks, then raise to 0.5 mg once weekly.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
Adult maintenance dosing is 2.4 mg once weekly (recommended) or 1.7 mg once weekly.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Start Ozempic at 0.25 mg once weekly for 4 weeks; this starter dose is not effective for glycemic control.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
After 4 weeks at 0.25 mg weekly, raise the dose to 0.5 mg weekly.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Studied populations
Who was represented in a study, label, or registry record.
Ozempic is used with diet and exercise for adults with type 2 diabetes that isn’t well controlled.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Ozempic can be used alone in patients who cannot take metformin.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In adults, Wegovy is indicated for weight management for BMI ≥30 kg/m2, or BMI ≥27 to <30 kg/m2 with at least one weight-related comorbidity.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
RYBELSUS and OZEMPIC tablets are not established as safe or effective in pediatric patients.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Ozempic can be used alone if a patient can’t take metformin.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Identity
Ingredient, molecule, and product identity statements.
Oral semaglutide was evaluated in the included randomized trials.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide was one of the agents assessed for laryngeal manifestations at 6 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide (SEMA) is a GLP-1 analogue.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema is a fixed-dose combination that includes semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
IcoSema is a once-weekly treatment that combines semaglutide with basal insulin icodec.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide is listed as a protein.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this study, semaglutide was treated as a GLP-1 receptor agonist (GLP-1RA).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema combines cagrilintide with semaglutide in a fixed dose.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a peptidomimetic agonist of the GLP-1 receptor.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide is a GLP-1 receptor agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
OZEMPIC contains semaglutide, a human GLP-1 receptor agonist (GLP-1 analog).
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
CagriSema is a fixed-dose combination that includes semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is described as a GLP-1 receptor agonist used for weight loss.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Wegovy’s active substance is semaglutide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Cagrilintide-semaglutide combines cagrilintide with semaglutide, and semaglutide is a GLP-1 receptor agonist.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The INFORM survey asked US adults using injectable semaglutide for weight management about perceived changes in “food noise.”
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a GLP-1 receptor agonist (GLP-1RA).
2 cited sources · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records. 2 publication group(s) lack a resolved study identity.
Semaglutide is a once-weekly GLP-1 receptor agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Oral semaglutide is included in the GLP-1 receptor agonist (GLP-1RA) medication class.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Oral semaglutide is an oral GLP-1 receptor agonist therapy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
WEGOVY injection contains semaglutide, a human GLP-1 receptor agonist (GLP-1 analog).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Ozempic contains semaglutide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide tablets contain semaglutide, a GLP-1 receptor agonist, and semaglutide is 94% homologous to human GLP-1.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide is a GLP-1 receptor agonist assessed for weight management.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a GLP-1 receptor agonist.
2 cited sources · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records. 2 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists and related therapies have transformed obesity medicine.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a GLP-1 receptor agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Rybelsus contains semaglutide as its active substance.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide is a GLP-1 receptor agonist (GLP-1RA).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a GLP-1 receptor agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this IBS study, semaglutide was one of the GLP-1 receptor agonists patients started.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Rybelsus contains semaglutide as its active substance.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide (Ligand ID: 9724) is a peptide; its INN is semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CT130 was designed from semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a GLP-1 receptor agonist (GLP1-RA).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
OZEMPIC is a semaglutide injection, and semaglutide is a human GLP-1 receptor agonist (GLP-1 analog).
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
OZEMPIC is an injection that contains semaglutide, a human GLP-1 receptor agonist (GLP-1 analog).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide is a GLP-1 receptor agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
RYBELSUS and OZEMPIC tablets contain semaglutide, a GLP-1 receptor agonist.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
"Hunger pain" was defined as extreme hunger with no satiety and constant thoughts about food.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a long-acting GLP-1 receptor agonist approved for chronic weight management.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema is a fixed-dose combination that includes semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a glucagon-like peptide-1 analogue and is part of the once-weekly combination therapy IcoSema (with basal insulin icodec).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
IcoSema combines basal insulin icodec with semaglutide in a fixed ratio.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is described as an antidiabetic drug studied (with acarbose) in a rat model of STZ-induced diabetic nephropathy.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a GLP-1 receptor agonist approved to treat type 2 diabetes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Ozempic contains semaglutide, a GLP-1 receptor agonist (GLP-1 analog).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide is a GLP-1 receptor agonist.
4 cited sources · 1 linked study ID · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 4 source records. 3 publication group(s) lack a resolved study identity.
Oral semaglutide is a GLP-1 receptor agonist therapy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a glucagon-like peptide-1 analogue.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a GLP-1 receptor agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide made up 76.6% of GLP-1RA starts in this study.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
OZEMPIC contains semaglutide, a human GLP-1 receptor agonist (GLP-1 analog).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Ozempic injection contains semaglutide, a human GLP-1 receptor agonist made with a peptide backbone produced by yeast fermentation.
6 cited sources · 6 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
7 cited passages across 6 source records.
Semaglutide is a GLP-1 receptor agonist (GLP-1 RA).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 analogs primarily exist as micelle-like associations when free in aqueous solution.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
RYBELSUS and OZEMPIC tablets contain semaglutide, a GLP-1 receptor agonist made by yeast fermentation.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Semaglutide was one of the GLP-1 receptor agonists counted as exposure in this study.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The included studies evaluated semaglutide exposure in pregnancy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema combines cagrilintide and semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema is a fixed-ratio combination of semaglutide and cagrilintide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a GLP-1R ligand.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a GLP-1 receptor agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a commonly used GLP-1 agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Additional research & classification gaps
260 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (260)
2 cited sources · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Semaglutide is taken once a week (per standard of care).
Research context only—not evidence of a treatment effect.
- These highlights do not include all the information needed to use OZEMPIC®safely and effectively. See full prescribing information for OZEMPIC.OZEMPIC (semaglutide) injection, for subcutaneous useInitial U.S. Approval: 2017
•Administer OZEMPIC once weekly, on the same day each week, at any time of the day, with or without meals.•Inject OZEMPIC subcutaneously to the abdomen, thigh, or upper arm.
- Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment
DRUG | Semaglutide | FDA-approved GLP-1 receptor agonist administered once weekly per standard of care
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For incretin drugs beyond liraglutide and tirzepatide, the evidence is mostly indirect because trials usually targeted obesity or cardiometabolic outcomes, not sleep outcomes.
Research context only—not evidence of a treatment effect.
- Incretin-Based Therapies in Obesity-Related Obstructive Sleep Apnea: A Narrative Review of Evidence Tiers and Mechanistic Plausibility.
evidence from other incretin agents also remains largely indirect because most trials were designed for obesity or cardiometabolic endpoints rather than sleep outcomes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide 2.4 mg was cost-effective under a €30,000 per QALY threshold.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
Semaglutide 2.4 mg was shown to be cost-effective under a cost-effectiveness threshold of €30,000/QALY.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The analysis compared semaglutide 2.4 mg plus diet/exercise versus diet/exercise alone for obesity treatment in Spain.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
The aim of this study was to evaluate the cost-effectiveness of semaglutide 2.4 mg in combination with D&E compared with D&E alone in the treatment of patients with obesity in Spain.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
TikTok videos had higher JAMA scores than Bilibili videos (median 3 vs. 1, p< 0.001).
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
TikTok videos had significantly higher JAMA scores than Bilibili videos (median 3 vs. 1,p< 0.001),
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
ATR-FTIR findings were consistent with LC-HRMS and chromatographic data.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
ATR-FTIR results were complemented by liquid chromatography-high-resolution mass spectrometry (LC-HRMS), showing consistency between the spectroscopic, mass spectrometric and chromatographic data.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A systematic review and meta-analysis compared oral and subcutaneous semaglutide for type 2 diabetes management.
Research context only—not evidence of a treatment effect.
- Assessment of noninferiority of oral vs subcutaneous semaglutide: a systematic review and meta-analysis.
This systematic review and meta‑analysis is the first to comprehensively compare oral and subcutaneous semaglutide for type 2 diabetes (T2D) management.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a model of 1000 US adolescents ages 12 to 26, semaglutide vs phentermine-topiramate had an ICER of $166,513 per QALY under perfect access.
Research context only—not evidence of a treatment effect.
- pubmed-42233337
Phentermine-topiramate (vs. lifestyle) yielded an ICER of 2025 US$112,141/QALY, and semaglutide (vs. phentermine-topiramate) yielded $166,513/QALY under perfect access.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Eye disorders were reported more often with semaglutide than with liraglutide (ROR 2.67; 95% CI 1.54-4.63) and dulaglutide (ROR 1.89; 95% CI 1.30-2.75).
Research context only—not evidence of a treatment effect.
- Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs).
Eye disorders were more frequently reported with semaglutide than liraglutide (ROR 2.67; 95% CI 1.54-4.63) and dulaglutide (ROR 1.89; 95% CI 1.30-2.75).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide 2.4 mg was included only as a supplementary non-governmental retail scenario.
Research context only—not evidence of a treatment effect.
- pubmed-42565180
Liraglutide, extended-release naltrexone/bupropion, and extended-release phentermine/topiramate were modeled, while semaglutide 2.4 mg served as a supplementary non-governmental retail scenario.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the model, semaglutide 2.4 mg plus diet and exercise was estimated to be a cost-effective option in Spain for adults with obesity versus diet and exercise alone.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
On the basis of the model-based analysis, semaglutide 2.4 mg, in combination with D&E, was estimated to be a cost-effective therapeutic alternative in Spain for adults with obesity, compared to treatment based on D&E alone.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Suicidal ideation was disproportionately reported with semaglutide versus dulaglutide (ROR 6.49; 95% CI 1.57-26.81).
Research context only—not evidence of a treatment effect.
- Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs).
Suicidal ideation was disproportionately reported with semaglutide (ROR 6.49; 95% CI 1.57-26.81) and liraglutide (ROR 8.61; 95% CI 1.87-39.45) compared with dulaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide had high value compared with liraglutide.
Research context only—not evidence of a treatment effect.
- Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.
Semaglutide had low value compared with naltrexone-bupropion and phentermine-topiramate and high value compared with liraglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
ATR-FTIR findings for semaglutide formulations were consistent with LC-HRMS and chromatographic data.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
ATR-FTIR results were complemented by liquid chromatography-high-resolution mass spectrometry (LC-HRMS), showing consistency between the spectroscopic, mass spectrometric and chromatographic data.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This study compared semaglutide 2.4 mg plus diet and exercise vs diet and exercise alone for obesity treatment in Spain using a model.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
The aim of this study was to evaluate the cost-effectiveness of semaglutide 2.4 mg in combination with D&E compared with D&E alone in the treatment of patients with obesity in Spain.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Complete tumour remission was 73.9% with semaglutide, versus 85.0% with DEAR and 60.0% with sleeve gastrectomy.
Research context only—not evidence of a treatment effect.
- pubmed-42495930
The DEAR group showed more stable metabolic improvements and the highest complete tumour remission rate (85.0%), followed by the semaglutide group (73.9%) and the sleeve gastrectomy group (60.0%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide 2.4 mg is described as a high-cost non-governmental retail scenario, not an expected institutional procurement estimate.
Research context only—not evidence of a treatment effect.
- pubmed-42565180
Liraglutide 3.0 mg and semaglutide 2.4 mg represent high-cost non-governmental retail scenarios rather than expected institutional procurement estimates.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study aimed to compare the cost-effectiveness of semaglutide 2.4 mg plus diet and exercise versus diet and exercise alone for obesity treatment in Spain.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
The aim of this study was to evaluate the cost-effectiveness of semaglutide 2.4 mg in combination with D&E compared with D&E alone in the treatment of patients with obesity in Spain.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Estimated generic semaglutide costs were $28 to $140 per person-year for injectable and $186 to $380 per person-year for oral formulations.
Research context only—not evidence of a treatment effect.
- How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access.
Estimated generic injectable costs ranged from $28 to $140 per person-year; oral formulations ranged from $186 to $380 per person-year.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide 2.4 mg is described as a high-cost non-governmental retail scenario, not an expected institutional procurement estimate.
Research context only—not evidence of a treatment effect.
- pubmed-42565180
Liraglutide 3.0 mg and semaglutide 2.4 mg represent high-cost non-governmental retail scenarios rather than expected institutional procurement estimates.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide’s safety profile is similar to other GLP-1RAs.
Research context only—not evidence of a treatment effect.
- Safety of Semaglutide.
the established safety profile for semaglutide is similar to that of other GLP-1RAs
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide had low value compared with naltrexone-bupropion.
Research context only—not evidence of a treatment effect.
- Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.
Semaglutide had low value compared with naltrexone-bupropion
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study compared lifestyle therapy, lifestyle plus semaglutide, and bariatric surgery for non-invasive markers of hepatic steatosis and fibrosis.
Research context only—not evidence of a treatment effect.
- Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLD.
This study compared the effects of lifestyle therapy, lifestyle plus semaglutide, and bariatric surgery on non-invasive markers of hepatic steatosis and fibrosis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1-based medications should not be treated as main painkillers or as substitutes for standard pain care.
Research context only—not evidence of a treatment effect.
- GLP-1-Based Therapies in Pain Medicine: A Narrative Review and Expert Opinion on Obesity-Related Low Back and Knee Pain.
GLP-1-based medications should not be viewed as primary analgesics or replacements for standard pain evaluation, rehabilitation, pharmacologic care, or interventional treatment.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This FAERS study included comparative analyses versus semaglutide.
Research context only—not evidence of a treatment effect.
- Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database.
Time-to-onset and comparative analyses versus semaglutide were conducted.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide had low value compared with phentermine-topiramate.
Research context only—not evidence of a treatment effect.
- Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.
Semaglutide had low value compared with naltrexone-bupropion and phentermine-topiramate
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide 2.4 mg was cost-effective under a €30,000 per QALY threshold.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
Semaglutide 2.4 mg was shown to be cost-effective under a cost-effectiveness threshold of €30,000/QALY.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
TikTok had higher JAMA scores than Bilibili (median 3 vs. 1, p< 0.001), while GQS and mDISCERN were similar.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
TikTok videos had significantly higher JAMA scores than Bilibili videos (median 3 vs. 1,p< 0.001), while GQS and mDISCERN scores were comparable between platforms.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 analog micelle aggregation contrasts with globular protein aggregation, which is typically dominated by the classical hydrophobic effect.
Research context only—not evidence of a treatment effect.
- Anisotropic Electrostatics in the Instability of GLP‑1 Analog Micelles: Effects of Electrolytes, Denaturants, pH, and Temperature.
This behavior contrasts with globular protein aggregation, typically dominated by the classical hydrophobic effect.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Only 2.7% of the semaglutide-related videos mainly discussed blood-sugar–lowering effects.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
only 2.7% primarily discussed hypoglycemic effects.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With semaglutide in ESRD, mean weight change at 12-months was -7.00 kg.
Research context only—not evidence of a treatment effect.
- Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
and -7.00 kg (95% CI: -11.38, -2.61; I2= 79.2%), respectively.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide has beneficial metabolic and cardiovascular actions.
Research context only—not evidence of a treatment effect.
- Safety of Semaglutide.
Given the beneficial metabolic and cardiovascular actions of semaglutide
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Face validity exceeded a 70% consensus threshold for clinicians and pharmacists.
Research context only—not evidence of a treatment effect.
- pubmed-42602345
Face validity exceeded the 70% consensus threshold for both validator groups.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Baseline C-reactive protein did not significantly change semaglutide’s treatment effects in meta-regression.
Research context only—not evidence of a treatment effect.
- Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.
meta-regression analyses did not identify significant modification of treatment effects by baseline C-reactive protein levels
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 40 years in the model, semaglutide 2.4 mg plus diet and exercise added 0.1049 QALYs vs diet and exercise alone.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
Compared with D&E, semaglutide 2.4 mg in combination with D&E generated an additional 0.1049 QALYs
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Whether the day of the week affects outcomes, adherence, or tolerability with semaglutide or tirzepatide remains unexplored.
Research context only—not evidence of a treatment effect.
- Is There a Better Day of the Week to Administer Semaglutide or Tirzepatide? A Systematic Literature Review.
the potential impact of administration timing-specifically, the day of the week-on clinical outcomes, adherence, and tolerability remains unexplored.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract states evidence supports early nutrition assessment, focusing on protein and diet quality, plus coordinated resistance and aerobic exercise.
Research context only—not evidence of a treatment effect.
- Medical nutrition therapy in incretin-treated obesity-related heart failure with preserved ejection fraction.
Available evidence supports early nutrition assessment, attention to protein and overall diet quality, and coordinated resistance and aerobic exercise,
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At the base-case price, the model estimated a 0.911 probability semaglutide is cost-effective at 100,000 €/QALY.
Research context only—not evidence of a treatment effect.
- Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.
At the base-case price, the probability that semaglutide is cost-effective at 100,000 €/QALY was 0.911, rising with further price reductions.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The ICER for semaglutide 2.4 mg plus diet and exercise vs diet and exercise alone was €25,589 per QALY.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
resulting in an incremental cost-effectiveness ratio of €25,589/QALY.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 40 years, semaglutide 2.4 mg plus diet and exercise generated 0.1049 additional QALYs vs diet and exercise alone.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
Compared with D&E, semaglutide 2.4 mg in combination with D&E generated an additional 0.1049 QALYs
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Oral semaglutide is challenging because it has limited gastrointestinal stability, poor epithelial permeability, and low affinity for lipid-based delivery systems.
Research context only—not evidence of a treatment effect.
- Microfluidic-assisted formulation of hydrophobic ion pairing-based solid lipid nanoparticles for semaglutide delivery.
Despite its clinical efficacy, oral administration remains challenging because of its limited gastrointestinal stability, poor epithelial permeability, and low affinity for lipid-based delivery systems.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists, including semaglutide, produce robust and sustained weight loss.
Research context only—not evidence of a treatment effect.
- pubmed-42550908
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, produce robust and sustained weight loss, yet the central mechanisms supporting their long-term efficacy remain incompletely understood.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Baseline hsCRP predicted future major adverse cardiovascular events.
Research context only—not evidence of a treatment effect.
- pubmed-42610271
was prognostic of future MACEs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
11CP-17B, 11CP-17N, and 11CP-19N had the best stability profiles.
Research context only—not evidence of a treatment effect.
- Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
and 11CP-17B, 11CP-17N, and 11CP-19N showed the most favourable stability profiles.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Follow-on/compounded semaglutide products had impurity profiles that differed from originators, including amino acid deletions/additions and unidentified impurities.
Research context only—not evidence of a treatment effect.
- Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists.
The follow-on drug substance and follow-on or compounded products had distinct impurity profiles (amino acid deletions/additions and unidentified impurities) versus the originators.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Clinicians rated the semaglutide algorithm with I-CVI 0.6 to 1.0 and S-CVI/Ave 0.89 across three rounds.
Research context only—not evidence of a treatment effect.
- pubmed-42602345
For clinicians, the I-CVI ranged from 0.6 to 1.0, with an overall S-CVI/Ave of 0.89 across three rounds.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With GLP-1 drugs like semaglutide, up to 45% of the weight loss can be from skeletal muscle loss.
Research context only—not evidence of a treatment effect.
- pubmed-42262870
While glucagon-like peptide-1 receptor agonists (GLP-1RAs) like semaglutide are effective in treating obesity, up to 45% of the resulting weight loss can be attributed to skeletal muscle loss.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After starting semaglutide, median FNQ was 6 (IQR 3–10).
Research context only—not evidence of a treatment effect.
- Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey.
After initiation of semaglutide, the median FNQ score was 6 (IQR 3-10).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Oral semaglutide lowered HbA1c by 1.16 percentage points (95% CI, -1.22 to -1.09).
Research context only—not evidence of a treatment effect.
- Assessment of noninferiority of oral vs subcutaneous semaglutide: a systematic review and meta-analysis.
Both formulations of semaglutide significantly reduced the level of glycated hemoglobin (HbA1c), that is, oral by 1.16 percentage points (95% CI, -1.22 to -1.09)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After starting semaglutide, triptan use declined by -13 DDD/month/10,000 (95% CI: -25 to -1.3), equal to a 7% reduction at 12 months (RR 0.93; 0.88-0.97).
Research context only—not evidence of a treatment effect.
- pubmed-42557547
Before initiation, triptan use increased over time; after initiation, this trend reversed, showing a decline of -13 DDD/month/10,000 (95% CI: -25 to -1.3), corresponding to a 7% relative reduction at 12 months (RR 0.93; 0.88-0.97).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Aggregation caused by NaCl and Gdn+ was semi-irreversible.
Research context only—not evidence of a treatment effect.
- Anisotropic Electrostatics in the Instability of GLP‑1 Analog Micelles: Effects of Electrolytes, Denaturants, pH, and Temperature.
Aggregation caused by both NaCl and Gdn+was semi-irreversible.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Most videos focused on weight loss (82.2%); only 2.7% mainly discussed hypoglycemic effects.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
Most videos focused on weight loss (82.2%), while only 2.7% primarily discussed hypoglycemic effects.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The reduction in triptan use mainly came from lower use among prevalent triptan users (RR 0.86; 0.82-0.90), not from changes in new-user rates.
Research context only—not evidence of a treatment effect.
- pubmed-42557547
This decrease primarily reflected a reduction in DDD consumption among prevalent users (RR 0.86; 0.82-0.90) rather than a change in monthly rates of new users.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The authors conclude semaglutide has substantial budget impact, so affordability and pricing are critical.
Research context only—not evidence of a treatment effect.
- Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.
Yet it generates substantial budget impact, indicating that affordability and pricing will be critical for its sustainable implementation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Under perfect access in the model, semaglutide vs phentermine-topiramate had an ICER of $166,513/QALY.
Research context only—not evidence of a treatment effect.
- pubmed-42233337
Phentermine-topiramate (vs. lifestyle) yielded an ICER of 2025 US$112,141/QALY, and semaglutide (vs. phentermine-topiramate) yielded $166,513/QALY under perfect access.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Pharmacists found all semaglutide algorithm items met the content-validity threshold in both rounds (I-CVI ≥0.83; P < 0.05).
Research context only—not evidence of a treatment effect.
- pubmed-42602345
Among pharmacists, all items met the prespecified content validity threshold for both rounds (I-CVI ≥0.83; P < 0.05).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Median scores were GQS 4.0 (3.0-4.0), mDISCERN 4.0 (3.0-5.0), and JAMA 2.0 (1.0-3.0).
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
The overall median scores were 4.0 (3.0-4.0) for GQS, 4.0 (3.0-5.0) for mDISCERN, and 2.0 (1.0-3.0) for JAMA.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Oral semaglutide tablets have limited absorption because semaglutide is hydrophilic and unstable to enzymes in the GI tract.
Research context only—not evidence of a treatment effect.
- pubmed-42349668
oral tablets are more convenient but suffer from limited absorption due to SET's hydrophilicity and enzymatic instability in the gastrointestinal tract
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema reduced percent body weight versus placebo (MD: -5.98%).
Research context only—not evidence of a treatment effect.
- Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In Australia (May 2024–April 2025), semaglutide made up 63.3% of GLP-1 medicines used for type 2 diabetes.
Research context only—not evidence of a treatment effect.
- Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.
In the year May 2024-April 2025, the majority of GLP-1 medicines used were semaglutide (63.3%) and tirzepatide (30.7%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The NAION cases in this study were diagnosed between 2018-2024.
Research context only—not evidence of a treatment effect.
- pubmed-42556433
A retrospective, multi-center, case control study of the CDR of NAION cases diagnosed between 2018-2024
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the simulations, higher insulin resistance made fibroblasts harder to activate and less likely to cycle under the same mechanical stress.
Research context only—not evidence of a treatment effect.
- A Computational Trial of Dermal Mechanotransduction in GLP-1 Receptor Agonist-Associated Premature Facial Ageing.
Higher IR raised the activation threshold from 36.8 to 47.9 kPa and reduced max cycling probability from 0.34 to 0.21.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The F10 formulation (1:18 semaglutide:DOTAP; 10% w/w peptide) had particle size <300 nm, almost complete encapsulation, and a highly positive zeta potential.
Research context only—not evidence of a treatment effect.
- Microfluidic-assisted formulation of hydrophobic ion pairing-based solid lipid nanoparticles for semaglutide delivery.
Among the various formulations prepared, the one prepared with a molar ratio semaglutide: DOTAP of 1:18 and a peptide concentration of 10% (w/w) (F10) showed the best results, combining particle sizes of less than 300 nm with almost complete encapsulation efficiency and a highly positive ζ-potential.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Pharmacists’ ratings met the prespecified content validity threshold in both rounds (I-CVI ≥0.83; P < 0.05).
Research context only—not evidence of a treatment effect.
- pubmed-42602345
Among pharmacists, all items met the prespecified content validity threshold for both rounds (I-CVI ≥0.83; P < 0.05).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Tirzepatide is stated to lower the risk of worsening heart failure.
Research context only—not evidence of a treatment effect.
- Medical nutrition therapy in incretin-treated obesity-related heart failure with preserved ejection fraction.
and, for tirzepatide, a lower risk of worsening heart failure.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With imperfect access, semaglutide’s cost-effectiveness dropped by 11%, and averted obesity cases fell from 57% to 3%.
Research context only—not evidence of a treatment effect.
- pubmed-42233337
Under imperfect access, cost-effectiveness and health gains were reduced. Cost-effectiveness was reduced by 11%, and averted obesity cases decreased from 57% to 3% for semaglutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the model, ICERs depended on medication costs, efficacy, and discontinuation (including for semaglutide as a modeled medication).
Research context only—not evidence of a treatment effect.
- pubmed-42233337
ICERs were sensitive to medication characteristics (costs, efficacy, discontinuation) and health utilities.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Oral semaglutide 14 mg was linked to more CAVI improvement than 3 mg or 7 mg.
Research context only—not evidence of a treatment effect.
- Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes.
Oral semaglutide of 14 mg was associated with greater improvement than 3 and 7 mg
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In Australia since May 2020, most growth in private access to GLP-1 diabetes medicines was driven by semaglutide.
Research context only—not evidence of a treatment effect.
- Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.
Since May 2020, total sales of GLP-1 medicines indicated for T2D increased almost 10-fold. Most growth was in private access, driven by semaglutide and rapid uptake of tirzepatide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema reduced HbA1c versus placebo.
Research context only—not evidence of a treatment effect.
- Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg), waist circumference (MD: -10.91 cm), systolic blood pressure, and HbA1c.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The primary histology endpoints were MASH resolution without worse fibrosis, at least a 1-point NAS improvement without worse fibrosis, and at least a 1-stage fibrosis improvement without worse MASH.
Research context only—not evidence of a treatment effect.
- pubmed-42605535
Primary histological endpoints included resolution of MASH without worsening fibrosis, ≥ 1-point improvement in the non-alcoholic fatty liver disease (NAFLD) activity score without worsening fibrosis and ≥ 1-stage improvement in fibrosis without worsening MASH.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By 2 years, weight regain occurred more often with semaglutide therapy (55.6%) than with the DEAR programme (14.3%) (p= 0.037).
Research context only—not evidence of a treatment effect.
- pubmed-42495930
By 2 years, weight regain was less frequent in the DEAR group (14.3%) than in the semaglutide (55.6%) and sleeve gastrectomy (66.7%) groups (p= 0.037).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Subcutaneous semaglutide 1 mg once-weekly lowered fasting blood glucose versus placebo at 30 weeks (MD = -1.93, 95% CI [-2.81; -1.04]).
Research context only—not evidence of a treatment effect.
- Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.
and fasting blood glucose (MD = -1.93, 95% CI [-2.81; -1.04]) versus placebo at 30 weeks
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide reduces PANoptosis in hippocampal neurons.
Research context only—not evidence of a treatment effect.
- HIF-1 plays a dual regulatory role in hippocampal neuronal PANoptosis in Alzheimer's disease via the HK2/VDAC1/NLRP3 axis and RIPK3 signaling.
Finally, we uncovered that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), mitigates hippocampal neuronal PANoptosis
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide was originally developed for glycemic control.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
Semaglutide, a glucagon-like peptide-1 receptor agonist originally developed for glycemic control, has recently gained widespread attention for its weight-loss effects.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a German health-insurance economic model, semaglutide (vs placebo) raised costs and QALYs over 5 years, with an ICER of 30,443 €/QALY and a positive incremental net monetary benefit.
Research context only—not evidence of a treatment effect.
- Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.
Over 5 years, semaglutide increased total costs (2025 €) (17,690.5 € versus 12,748.6 €) and QALYs (3.371 versus 3.208), yielding an ICER of 30,443 €/QALY and a positive incremental net monetary benefit.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The primary outcome was mean body-weight reduction from baseline after GLP1RA-based treatment in ESRD.
Research context only—not evidence of a treatment effect.
- Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
Primary outcome was mean reduction in body weight from baseline following treatment with GLP1RA-BT.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
They were able to make a library of modified peptides, confirmed with qualitative and quantitative analytical data.
Research context only—not evidence of a treatment effect.
- Harnessing the Reactivity of Sulfinate Salts With Cystine: An Umpolung Approach to Residue-Specific Peptide Modification.
A library of modified peptides was accessible, as confirmed by qualitative and quantitative analytical data, providing valuable insights into the matched reactivity of specific radical/disulfide substrate pairings.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The optimized SD@SEDDS had drug loading of 2.64 mg/g.
Research context only—not evidence of a treatment effect.
- pubmed-42349668
high drug loading (2.64 mg/g)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study compared total weight loss for up to 3 years after treatment using weighted and mixed-model analyses, with intention-to-treat and per-protocol approaches.
Research context only—not evidence of a treatment effect.
- Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery.
Total weight loss (TWL) was compared up to 3 years post treatment with inverse probability weighting and mixed linear models. Intention-to-treat (any GLP-1RA) and per-protocol (1 year of continuous GLP-1RA orders) analyses were performed.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Implementation and evaluation of the semaglutide algorithm in Nova Scotia community pharmacy clinics are underway.
Research context only—not evidence of a treatment effect.
- pubmed-42602345
Implementation and evaluation in Nova Scotia community pharmacy clinics are underway.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Most stapled analogues were more stable in serum and against proteolysis than semaglutide.
Research context only—not evidence of a treatment effect.
- Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Most stapled analogues showed improved serum and proteolytic stability relative to semaglutide,
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists are established treatments for metabolic disease.
Research context only—not evidence of a treatment effect.
- pubmed-42573665
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are established treatments for metabolic disease
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
No single baseline feature reliably predicts who will respond.
Research context only—not evidence of a treatment effect.
- Responders Vs. Non-Responders or How to Predict the Response to GLP-1 or GLP-1/GIP Receptor Agonist Therapy.
No single baseline characteristic reliably predicts response.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
The primary outcomes were changes in NT-proBNP, KCCQ score, and heart-failure hospitalization.
Research context only—not evidence of a treatment effect.
- Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.
Primary outcomes included changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP), Kansas City Cardiomyopathy Questionnaire (KCCQ) score, and heart-failure hospitalization.
- Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.
Primary outcomes included changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP), Kansas City Cardiomyopathy Questionnaire (KCCQ) score, and heart-failure hospitalization.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Adding an AI digital assistant did not independently improve medication adherence.
Research context only—not evidence of a treatment effect.
- pubmed-42575845
Integrating an AI digital assistant did not independently improve medication adherence;
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The main outcome measured was percent change in body weight from baseline.
Research context only—not evidence of a treatment effect.
- Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.
The primary outcome was the percentage change in body weight from baseline.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide (SEMA) is described as highly effective, but limited by low oral bioavailability.
Research context only—not evidence of a treatment effect.
- Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.
Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs), particularly semaglutide (SEMA), exhibit robust therapeutic efficacy, their clinical application is limited by low oral bioavailability.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Under light exposure, compounded semaglutide differed significantly from originator products in strength, total impurities, and high-molecular-weight protein levels.
Research context only—not evidence of a treatment effect.
- Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists.
Significant disparity in strength, impurity sum, and high-molecular-weight protein level were observed between compounded semaglutide and originator products when exposed to light.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study defined 6-month semaglutide adherence as at least 6 orders fulfilled within 183 days.
Research context only—not evidence of a treatment effect.
- pubmed-42575845
The primary endpoint was 6-month medication adherence (≥ 6 orders fulfilled within 183 days).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 40 years in the model, semaglutide 2.4 mg plus diet and exercise cost €2685 more than diet and exercise alone.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
Compared with D&E, semaglutide 2.4 mg in combination with D&E generated an additional 0.1049 QALYs and a €2685 increase in costs over 40 years
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Among 225 semaglutide-related videos, 82.2% focused on weight loss.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
A total of 225 videos were included (107 from Bilibili and 118 from TikTok). Most videos focused on weight loss (82.2%), while only 2.7% primarily discussed hypoglycemic effects.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With semaglutide in ESRD, BMI change at 6-months was -1.26 kg/m2.
Research context only—not evidence of a treatment effect.
- Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
-1.26 kg/m2(95% CI: -1.90, -0.62; I2= 0.0%),
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists (such as semaglutide) treat Type 2 Diabetes and obesity mainly by improving blood sugar control, reducing appetite, delaying stomach emptying, and causing weight loss.
Research context only—not evidence of a treatment effect.
- pubmed-42434480
GLP-1 receptor agonists (e.g., semaglutide; GLP-1 RAs) treat Type 2 Diabetes and obesity, mainly by improving glycemic control, suppressing appetite, delaying gastric emptying, and inducing weight loss.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Clinician item-level content validity scores ranged from 0.6 to 1.0.
Research context only—not evidence of a treatment effect.
- pubmed-42602345
For clinicians, the I-CVI ranged from 0.6 to 1.0, with an overall S-CVI/Ave of 0.89 across three rounds.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With semaglutide in ESRD, BMI change at 12-months was -3.09 kg/m2.
Research context only—not evidence of a treatment effect.
- Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
and -3.09 kg/m2(95% CI: -5.28, -0.89; I2= 95.9%), respectively.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The model estimated €25,589 per QALY for semaglutide 2.4 mg plus diet/exercise versus diet/exercise alone.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
Compared with D&E, semaglutide 2.4 mg in combination with D&E generated an additional 0.1049 QALYs and a €2685 increase in costs over 40 years, resulting in an incremental cost-effectiveness ratio of €25,589/QALY.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Ramadan blood-glucose problems were mostly driven by the post-iftar period.
Research context only—not evidence of a treatment effect.
- GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study.
Dysglycaemia was driven predominantly by the post-iftar period.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide has important indirect evidence for obesity and cardiometabolic outcomes in the context of obstructive sleep apnea.
Research context only—not evidence of a treatment effect.
- Incretin-Based Therapies in Obesity-Related Obstructive Sleep Apnea: A Narrative Review of Evidence Tiers and Mechanistic Plausibility.
Semaglutide provides important indirect obesity and cardiometabolic evidence
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
MACE risk rose across baseline hsCRP groups <2, 2-<10, and ≥10 mg/L, and hsCRP was significantly associated with cardiovascular and all-cause death.
Research context only—not evidence of a treatment effect.
- pubmed-42610271
The risk of MACEs increased across baseline hsCRP level <2, 2-<10, and ≥10 mg/L subgroups, including significant associations with cardiovascular and all-cause death.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After starting semaglutide, the triptan-use trend reversed to a decline of -13 DDD per month per 10,000 (95% CI: -25 to -1.3).
Research context only—not evidence of a treatment effect.
- pubmed-42557547
Before initiation, triptan use increased over time; after initiation, this trend reversed, showing a decline of -13 DDD/month/10,000 (95% CI: -25 to -1.3)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study evaluated ATR-FTIR plus multivariate analysis as a rapid, non-destructive way to monitor structural changes and degradation in formulations containing semaglutide.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
This study aimed to evaluate the applicability of attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy in combination with multivariate data analysis as a rapid, non-destructive tool for monitoring structural changes and degradation in formulations containing semaglutide and liraglutide as model compounds.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Results supported ATR-FTIR plus multivariate analysis as a rapid way to assess semaglutide (as a peptide medicine) behavior under stress conditions.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
The results confirm the applicability of ATR-FTIR spectroscopy combined with multivariate data analysis as a powerful tool for rapid assessment of the behavior of peptide medicines under stress conditions.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With semaglutide in ESRD, mean weight change at 6-months was -3.68 kg.
Research context only—not evidence of a treatment effect.
- Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
-3.68 kg (95% CI: -5.71, -1.65; I2= 0.0%),
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Heterogeneity across studies was low for the primary outcomes.
Research context only—not evidence of a treatment effect.
- Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.
Between-study heterogeneity was low for primary outcomes
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By 2 years, weight regain was more common with semaglutide (55.6%) than with the DEAR programme (14.3%) (p= 0.037).
Research context only—not evidence of a treatment effect.
- pubmed-42495930
By 2 years, weight regain was less frequent in the DEAR group (14.3%) than in the semaglutide (55.6%) and sleeve gastrectomy (66.7%) groups (p= 0.037).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Face validity for the semaglutide algorithm exceeded a 70% consensus threshold in both validator groups.
Research context only—not evidence of a treatment effect.
- pubmed-42602345
Face validity exceeded the 70% consensus threshold for both validator groups.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The ICER for semaglutide 2.4 mg plus diet and exercise versus diet and exercise alone was €25,589 per QALY.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
resulting in an incremental cost-effectiveness ratio of €25,589/QALY.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The results supported using ATR-FTIR plus multivariate analysis for rapid assessment of peptide medicines under stress.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
The results confirm the applicability of ATR-FTIR spectroscopy combined with multivariate data analysis as a powerful tool for rapid assessment of the behavior of peptide medicines under stress conditions.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Subcutaneous semaglutide 1 mg once-weekly lowered HbA1c versus placebo at 30 weeks (MD = -1.72, 95% CI [-2.32; -1.12]).
Research context only—not evidence of a treatment effect.
- Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.
SC semaglutide 1 mg once-weekly showed higher reduction in HbA1c(MD = -1.72, 95% CI [-2.32; -1.12]),
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
F10 was stable in simulated gastrointestinal conditions and released semaglutide in a sustained way.
Research context only—not evidence of a treatment effect.
- Microfluidic-assisted formulation of hydrophobic ion pairing-based solid lipid nanoparticles for semaglutide delivery.
The F10 formulation demonstrated good stability under simulated gastrointestinal conditions and a sustained-release profile.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Subcutaneous semaglutide lowered HbA1c by 1.4 percentage points (95% CI, -1.47 to -1.33).
Research context only—not evidence of a treatment effect.
- Assessment of noninferiority of oral vs subcutaneous semaglutide: a systematic review and meta-analysis.
and subcutaneous by 1.4 percentage points (95% CI, -1.47 to -1.33).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study used version 26 of the Core Obesity Model (a Markov model) to project outcomes and costs over 40 years.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
The analyses were performed using version 26 of the Core Obesity Model, a Markov state transition model, to project health outcomes and costs at 40 years
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Weight lost (in kilograms) does not show whether treatment reduces harmful fat, preserves muscle function, or maintains nutrition.
Research context only—not evidence of a treatment effect.
- Medical nutrition therapy in incretin-treated obesity-related heart failure with preserved ejection fraction.
Yet kilograms lost do not reveal whether treatment preferentially reduces harmful adiposity, preserves muscle function, or maintains nutritional adequacy.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
With semaglutide, bigger hsCRP reductions were associated with more weight loss.
Research context only—not evidence of a treatment effect.
- pubmed-42610271
Greater reductions in ratio-to-baseline hsCRP with semaglutide were associated with greater weight loss
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study measured cognition using the elevated plus maze and novel object recognition tests.
Research context only—not evidence of a treatment effect.
- Semaglutide Attenuates Type 2 Diabetes-Induced Neurotoxicity by Modulating Neuroinflammation, Oxidative Stress, and Neuroapoptosis.
Cognitive function was evaluated using the elevated plus maze (EPM) and novel object recognition (NOR) paradigms.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The combined approach showed potential for stability monitoring, formulation studies, process control, and product authentication when structural changes are expected.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
As demonstrated in this proof-of-concept study, this integrated analytical approach indicates potential for application in stability monitoring, formulation studies, process control, and as part of a multi-analytical strategy for product authentication, particularly when structural alterations are expected.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The primary outcome was time to first kidney composite event: persistent 50% or greater eGFR reduction, kidney failure, kidney-related death, or cardiovascular-related death.
Research context only—not evidence of a treatment effect.
- Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.
The primary outcome in this pooled analysis was time to first occurrence of a kidney composite, defined as onset of persistent 50% or greater reduction in estimated glomerular filtration rate (eGFR), kidney failure (persistent eGFR <15 mL/min per 1·73 m2, or initiation of kidney replacement therapy), kidney-related death, or cardiovascular-related death.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Over 40 years, semaglutide 2.4 mg plus diet and exercise increased costs by €2685 vs diet and exercise alone.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
and a €2685 increase in costs over 40 years
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
Compared with D&E, semaglutide 2.4 mg in combination with D&E generated an additional 0.1049 QALYs and a €2685 increase in costs over 40 years, resulting in an incremental cost-effectiveness ratio of €25,589/QALY.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Higher starting CAVI was linked to less CAVI improvement.
Research context only—not evidence of a treatment effect.
- Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes.
whereas higher baseline CAVI was associated with an attenuated response.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By 12 months, 39% had HbA1c reduction ≥ 1%, 43% had ≥ 5% weight loss, and 23% met the composite endpoint.
Research context only—not evidence of a treatment effect.
- Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response.
Overall, 39% achieved an HbA1c reduction ≥ 1%, 43% achieved ≥ 5% weight loss, and 23% achieved the composite endpoint at 12 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
When AgRP circuits were disrupted, GLP-1 receptor agonists (including semaglutide) had reduced full weight-lowering effects.
Research context only—not evidence of a treatment effect.
- pubmed-42550908
Across complementary AgRP loss-of-function models, disruption of AgRP circuit integrity reduced the full weight-lowering effects of GLP-1RAs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the model, semaglutide 2.4 mg plus diet and exercise had an ICER of €25,589 per QALY vs diet and exercise alone over 40 years.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
resulting in an incremental cost-effectiveness ratio of €25,589/QALY.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Videos from medical professionals were linked to higher quality scores on all three tools, while commercial videos were linked to lower mDISCERN and GQS.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
In multivariable analyses, videos uploaded by medical professionals were consistently associated with higher quality scores across all three instruments, whereas commercial videos were associated with lower mDISCERN and GQS scores.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Overall, the median GQS score of the videos was 4.0 (3.0–4.0).
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
The overall median scores were 4.0 (3.0-4.0) for GQS
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
ΔCAVI was calculated as baseline CAVI minus follow-up CAVI; a positive ΔCAVI means arterial stiffness decreased (improved).
Research context only—not evidence of a treatment effect.
- Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes.
ΔCAVI was defined as baseline minus follow-up CAVI. Therefore, a positive ΔCAVI indicates a decrease (i.e., improvement) in arterial stiffness.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Secondary outcomes included BMI, glycaemia, and safety profile changes.
Research context only—not evidence of a treatment effect.
- Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
Secondary outcomes were changes in body mass index (BMI), glycaemia, and safety profile.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Versus diet and exercise alone, semaglutide 2.4 mg plus diet and exercise increased costs by €2685 over 40 years.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
and a €2685 increase in costs over 40 years
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists can restore bone marrow progenitor cell output toward a more vessel-regenerative profile.
Research context only—not evidence of a treatment effect.
- pubmed-42388102
GLP-1RAs can restore bone marrow progenitor cell output towards a more vessel regenerative profile.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The optimized SD@SEDDS formed a clear emulsion when diluted and had a particle size of 85.55 nm.
Research context only—not evidence of a treatment effect.
- pubmed-42349668
The optimized SD@SEDDS produced a clear emulsion upon dilution, with a uniform particle size of 85.55 nm
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the model, semaglutide vs placebo had an ICER of 82,237 €/QALY over 1 year.
Research context only—not evidence of a treatment effect.
- Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.
Over 1 year, the ICER was 82,237 €/QALY.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The method worked with unprotected amino acids, including histidine, tryptophan, and tyrosine.
Research context only—not evidence of a treatment effect.
- Harnessing the Reactivity of Sulfinate Salts With Cystine: An Umpolung Approach to Residue-Specific Peptide Modification.
The method was broadly compatible with a range of unprotected amino acids, including histidine, tryptophan, and tyrosine,
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the model, starting semaglutide 6 months before Sofwave worsened the outcome for high insulin-resistance phenotypes (90th percentile ΔAUC: -0.006).
Research context only—not evidence of a treatment effect.
- A Computational Trial of Dermal Mechanotransduction in GLP-1 Receptor Agonist-Associated Premature Facial Ageing.
Prolonged (6-month) pre-treatment was detrimental in high-IR phenotypes (90th percentile ΔAUC: -0.006).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 reduced adipogenesis and increased osteogenesis in BMSCs in a dose-dependent way.
Research context only—not evidence of a treatment effect.
- pubmed-42425087
GLP-1 suppressed adipogenesis and promoted osteogenesis of BMSCs in a dose-dependent manner.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema reduced body weight versus placebo (MD: -4.68 kg).
Research context only—not evidence of a treatment effect.
- Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With semaglutide in ESRD, mean weight change at 3-months was -3.09 kg.
Research context only—not evidence of a treatment effect.
- Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
Weight reduction with semaglutide after 3-, 6-, and 12-months therapy were -3.09 kg (95% confidence interval [CI]: -5.95, -0.24; I2= 58.1%),
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema reduced systolic blood pressure versus placebo.
Research context only—not evidence of a treatment effect.
- Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg), waist circumference (MD: -10.91 cm), systolic blood pressure, and HbA1c.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 receptor agonists reduce MACE, heart failure, and mortality through undetermined mechanisms independent of glycemic control.
Research context only—not evidence of a treatment effect.
- pubmed-42388102
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE), heart failure, and mortality through undetermined mechanisms independent of glycemic control.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In Spain, for adults with obesity, semaglutide 2.4 mg plus diet and exercise was estimated to be cost-effective vs diet and exercise alone.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
semaglutide 2.4 mg, in combination with D&E, was estimated to be a cost-effective therapeutic alternative in Spain for adults with obesity, compared to treatment based on D&E alone.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the simulations, starting semaglutide 6 months before treatment was harmful for high–insulin-resistance phenotypes (90th percentile ΔAUC: -0.006).
Research context only—not evidence of a treatment effect.
- A Computational Trial of Dermal Mechanotransduction in GLP-1 Receptor Agonist-Associated Premature Facial Ageing.
Prolonged (6-month) pre-treatment was detrimental in high-IR phenotypes (90th percentile ΔAUC: -0.006).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Most videos were about weight loss (82.2%); 2.7% mainly discussed hypoglycemic effects.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
Most videos focused on weight loss (82.2%), while only 2.7% primarily discussed hypoglycemic effects.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With semaglutide in ESRD, HbA1c change at 12 months was -0.75%.
Research context only—not evidence of a treatment effect.
- Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
and -0.75% (95% CI: -1.07, -0.43; I2= 61.6%), respectively.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In lab tests using dendritic cells from healthy donors, semaglutide samples showed potentially immunogenic peptides presented, with a different number/distribution than originator products.
Research context only—not evidence of a treatment effect.
- Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists.
For semaglutide and liraglutide, various potentially immunogenic peptides (distinct number/distribution vs originators) were presented on impurity-stimulated monocyte-derived dendritic cells from healthy donors.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
ATR-FTIR with multivariate analysis could be used as a rapid, non-destructive way to monitor structural changes and degradation in semaglutide-containing formulations.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
This study aimed to evaluate the applicability of attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy in combination with multivariate data analysis as a rapid, non-destructive tool for monitoring structural changes and degradation in formulations containing semaglutide and liraglutide as model compounds.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The authors conclude semaglutide appears cost-effective for HFpEF with obesity under base-case assumptions over longer horizons.
Research context only—not evidence of a treatment effect.
- Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.
Semaglutide appears cost-effective for HFpEF with obesity under the base-case assumptions and over longer analytic horizons.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
An “effective response” was defined as ΔCAVI ≥0.2.
Research context only—not evidence of a treatment effect.
- Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes.
A ΔCAVI of ≥0.2 was defined as an effective response.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study measured specific inflammation, oxidative stress, and apoptosis markers in brain tissue by ELISA.
Research context only—not evidence of a treatment effect.
- Semaglutide Attenuates Type 2 Diabetes-Induced Neurotoxicity by Modulating Neuroinflammation, Oxidative Stress, and Neuroapoptosis.
Neuroinflammatory markers (COX-2, TNF-α, and IL-6), oxidative stress biomarkers (MDA, GSH, and catalase), and apoptosis-associated proteins (Caspase-3, Bax, and Bcl-2) were measured in brain tissue homogenates using ELISA.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Overall clinician scale-level content validity (S-CVI/Ave) was 0.89 across three rounds.
Research context only—not evidence of a treatment effect.
- pubmed-42602345
For clinicians, the I-CVI ranged from 0.6 to 1.0, with an overall S-CVI/Ave of 0.89 across three rounds.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Even with short incubation times and a dry film approach that might affect conformation, clear early- and late-degradation changes were detected.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
Despite the relatively short incubation times and using a dry film approach which may introduce conformational changes, clear changes associated with early and advanced phases of degradation were detected.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 12 months after starting semaglutide, triptan use was 7% lower (RR 0.93; 0.88-0.97).
Research context only—not evidence of a treatment effect.
- pubmed-42557547
corresponding to a 7% relative reduction at 12 months (RR 0.93; 0.88-0.97).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Overall, the median JAMA benchmark score of the videos was 2.0 (1.0–3.0).
Research context only—not evidence of a treatment effect.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CagriSema reduced waist circumference versus placebo (MD: -10.91 cm).
Research context only—not evidence of a treatment effect.
- Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg), waist circumference (MD: -10.91 cm)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The model reported costs, QALYs, and ICERs.
Research context only—not evidence of a treatment effect.
- Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.
Outcomes included costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Current evidence does not support one best day of the week to take semaglutide or tirzepatide.
Research context only—not evidence of a treatment effect.
- Is There a Better Day of the Week to Administer Semaglutide or Tirzepatide? A Systematic Literature Review.
Current evidence does not support a specific optimal day of the week for semaglutide or tirzepatide administration.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Daily salt intake fell from 8.9 to 7.0 g/day after 3 months on semaglutide.
Research context only—not evidence of a treatment effect.
- pubmed-42552642
Notably, the daily salt intake also decreased significantly from 8.9 to 7.0 g/day.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide (a GLP-1 receptor agonist) is effective in treating obesity.
Research context only—not evidence of a treatment effect.
- pubmed-42262870
While glucagon-like peptide-1 receptor agonists (GLP-1RAs) like semaglutide are effective in treating obesity,
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Private access was estimated as sales minus PBS dispensings.
Research context only—not evidence of a treatment effect.
- Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.
we estimated private access as the difference between sales and PBS dispensings.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At week 24 (ITT LOCF), HbA1c fell by -1.50 (test) vs -1.65 (reference); the difference was 0.16 (95% CI: -0.16 to 0.47; P = 0.3266), supporting non-inferiority of the test product.
Research context only—not evidence of a treatment effect.
- pubmed-42598626
In the ITT (LOCF) set, at week-24, LSM change in HbA1c was -1.50 vs. -1.65 in test vs. reference group, respectively; LSM difference was 0.16 (95% CI: -0.16 to 0.47, P = 0.3266), confirming non-inferiority of the test product.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Median scores were GQS 4.0 (3.0-4.0), mDISCERN 4.0 (3.0-5.0), and JAMA 2.0 (1.0-3.0).
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
The overall median scores were 4.0 (3.0-4.0) for GQS, 4.0 (3.0-5.0) for mDISCERN, and 2.0 (1.0-3.0) for JAMA.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The analysis included 225 videos: 107 from Bilibili and 118 from TikTok.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
A total of 225 videos were included (107 from Bilibili and 118 from TikTok).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study aimed to assess semaglutide’s safety and efficacy versus placebo and other anti-hyperglycaemic agents in type 2 diabetes.
Research context only—not evidence of a treatment effect.
- Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.
To assess the safety and efficacy of semaglutide compared with placebo and other anti-hyperglycaemic agents in type 2 diabetes (T2DM).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
108 stapled peptide candidates were designed using modelling and virtual screening.
Research context only—not evidence of a treatment effect.
- Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
A total of 108 stapled peptide candidates were designed by structure-guided modelling and virtual screening.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
35 of the peptides were made and tested for characteristics.
Research context only—not evidence of a treatment effect.
- Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Among them, 35 peptides were synthesised and characterised.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Among 225 semaglutide-related videos, 2.7% primarily discussed hypoglycemic effects.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
A total of 225 videos were included (107 from Bilibili and 118 from TikTok). Most videos focused on weight loss (82.2%), while only 2.7% primarily discussed hypoglycemic effects.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The drop in triptan use mainly came from lower use among prevalent triptan users (RR 0.86; 0.82-0.90), not from fewer new users.
Research context only—not evidence of a treatment effect.
- pubmed-42557547
This decrease primarily reflected a reduction in DDD consumption among prevalent users (RR 0.86; 0.82-0.90) rather than a change in monthly rates of new users.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
“Stopping insulin” meant a first gap of 12 months or more in insulin prescription fills during 3 years of follow-up.
Research context only—not evidence of a treatment effect.
- Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation.
Insulin discontinuation, defined as the first gap in insulin prescription fills of 12 months or more over 3 years of follow-up.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Use was measured as units sold/dispensed and DDD/1000 population/day.
Research context only—not evidence of a treatment effect.
- Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.
We measured GLP-1 medicine use as number of units sold/dispensed and defined daily dose (DDD)/1000 population/day.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Systolic blood pressure dropped by -3.56 mmHg at 6 months.
Research context only—not evidence of a treatment effect.
- Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response.
SBP decreased by -3.56 mmHg (-6.17 to -0.96; p = 0.007) at 6 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this economic evaluation, semaglutide was cost-effective under $200,000 per QALY using 2025 pricing.
Research context only—not evidence of a treatment effect.
- pubmed-42233337
In this economic evaluation, phentermine-topiramate and semaglutide were cost-effective under $200,000/QALY, using 2025 pricing.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Since May 2020 in Australia, sales of GLP-1 medicines for type 2 diabetes rose almost 10-fold, mostly due to private access growth driven by semaglutide.
Research context only—not evidence of a treatment effect.
- Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.
Since May 2020, total sales of GLP-1 medicines indicated for T2D increased almost 10-fold. Most growth was in private access, driven by semaglutide and rapid uptake of tirzepatide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The conclusion states GLP-1 RA exposure around conception or in the first trimester is not significantly associated with HDP risk.
Research context only—not evidence of a treatment effect.
- Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.
Periconceptional or first-trimester exposure to GLP-1 RAs are not significantly associated with HDP risk.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide’s ChEMBL ID is CHEMBL2108724, and its preferred name is SEMAGLUTIDE.
Research context only—not evidence of a treatment effect.
- SEMAGLUTIDE
ChEMBL ID: CHEMBL2108724 Preferred name: SEMAGLUTIDE
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is also called Wegovy.
Research context only—not evidence of a treatment effect.
- SEMAGLUTIDE
NN-9535; Nn9535; NN9535; NNC 0113-0217; NNC-0113-0217; Ozempic; Rybelsus; Semaglutida; Semaglutide; Semaglutide component of cagrisema; Semaglutide component of nn1535 icosema; Semaglutide component of nn1535 laisema; Wegovy
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide 2.4 mg is a GLP-1 analogue.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
Subcutaneous semaglutide 2.4 mg, a glucagon-like peptide 1 analogue,
2 cited sources · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 2 source records. 1 publication group(s) lack a resolved study identity.
Oral semaglutide is described here as a long-acting GLP-1 analogue.
Research context only—not evidence of a treatment effect.
- Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body), and pharmacodynamics (the effect of the investigated drug on the body) of multiple doses of a long-acting GLP-1 analogue (oral semaglutide) and a carrier in healthy male subjects and male subjects with type 2 diabetes (T2D).
- Integrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies.
This medication class now includes oral formulations including oral semaglutide
- Integrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies.
This medication class now includes oral formulations including oral semaglutide and the first non-peptide oral GLP-1RA, orforglipron
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide 2.4 mg is a glucagon-like peptide 1 analogue.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
Subcutaneous semaglutide 2.4 mg, a glucagon-like peptide 1 analogue, has been approved by the European Medicines Agency as an adjunct to a reduced-calorie diet and increased physical activity (diet and exercise [D&E]) for the treatment of obesity.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
Subcutaneous semaglutide 2.4 mg, a glucagon-like peptide 1 analogue, has been approved by the European Medicines Agency as an adjunct to a reduced-calorie diet and increased physical activity (diet and exercise [D&E]) for the treatment of obesity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide was one of nine peptide-based GLP-1 receptor agonists measured using a multiplexed LC‑HRMS method.
Research context only—not evidence of a treatment effect.
- Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
A rapid, sensitive, and selective multiplexed liquid chromatography-high-resolution mass spectrometry (LC-HRMS) method was developed and validated for the identification and quantitation of nine structurally diverse peptide-based glucagon-like peptide-1 receptor agonists (GLP-1 RAs): bofanglutide, ecnoglutide, exenatide, liraglutide, mazdutide, retatrutide, semaglutide, survodutide, and tirzepatide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The paper is a targeted narrative review about GLP-1 receptor agonist users and issues relevant to surgery and body contouring.
Research context only—not evidence of a treatment effect.
- GLP-1 Receptor Agonists in Aesthetic Surgery: A Narrative Review on Perioperative Safety, Sarcopenic Morphologies, and Adapted Body Contouring Strategies.
A targeted narrative review of perioperative safety considerations, body-composition studies, and aesthetic/body contouring literature relevant to GLP-1 RA users.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is also called Rybelsus.
Research context only—not evidence of a treatment effect.
- SEMAGLUTIDE
NN-9535; Nn9535; NN9535; NNC 0113-0217; NNC-0113-0217; Ozempic; Rybelsus; Semaglutida; Semaglutide; Semaglutide component of cagrisema; Semaglutide component of nn1535 icosema; Semaglutide component of nn1535 laisema; Wegovy
2 cited sources · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records. 1 publication group(s) lack a resolved study identity.
Semaglutide is a GLP-1 receptor agonist.
Research context only—not evidence of a treatment effect.
- A Phase Ib Clinical Trial, Using Interleukin-2 (IL-2) and Semaglutide in Patients With Alzheimer's Disease
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, are a class of drugs currently used to treat diabetes and obesity.
- Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
Incretin-based therapies-glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide
4 cited sources · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 4 source records. 4 publication group(s) lack a resolved study identity.
Semaglutide is a glucagon-like peptide-1 receptor agonist.
Research context only—not evidence of a treatment effect.
- pubmed-42315078
Semaglutide is a glucagon-like peptide-1 receptor agonist that has been widely used in the treatment of diabetes and obesity.
- Microfluidic-assisted formulation of hydrophobic ion pairing-based solid lipid nanoparticles for semaglutide delivery.
Semaglutide is a glucagon-like peptide-1 receptor agonist widely used for the treatment of type 2 diabetes and obesity.
- Semaglutide for the treatment of obesity.
Semaglutide is a glucagon-like peptide-1 receptor agonist
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
Semaglutide, a glucagon-like peptide-1 receptor agonist originally developed for glycemic control, has recently gained widespread attention for its weight-loss effects.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is also called Ozempic.
Research context only—not evidence of a treatment effect.
- SEMAGLUTIDE
NN-9535; Nn9535; NN9535; NNC 0113-0217; NNC-0113-0217; Ozempic; Rybelsus; Semaglutida; Semaglutide; Semaglutide component of cagrisema; Semaglutide component of nn1535 icosema; Semaglutide component of nn1535 laisema; Wegovy
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is also called NN-9535.
Research context only—not evidence of a treatment effect.
- SEMAGLUTIDE
NN-9535; Nn9535; NN9535; NNC 0113-0217; NNC-0113-0217; Ozempic; Rybelsus; Semaglutida; Semaglutide; Semaglutide component of cagrisema; Semaglutide component of nn1535 icosema; Semaglutide component of nn1535 laisema; Wegovy
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
A 7.2 mg maintenance dose of semaglutide was recently introduced.
Research context only—not evidence of a treatment effect.
- Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.
The recent introduction of a 7.2 mg maintenance dose of semaglutide warrants particular attention.
- Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.
The recent introduction of a 7.2 mg maintenance dose of semaglutide warrants particular attention.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The model used KCCQ-CSS quartiles and death as health states.
Research context only—not evidence of a treatment effect.
- Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.
Health states were defined by Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) quartiles and death.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The absorption mechanism involved targeting ASBT and GLUT2 plus clathrin- and caveolae/lipid-mediated endocytosis.
Research context only—not evidence of a treatment effect.
- Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.
Mechanistic studies revealed a multivalent absorption pathway involving dual targeting of the apical sodium-dependent bile acid transporter (ASBT) and glucose transporter 2 (GLUT2), together with clathrin- and caveolae/lipid-mediated endocytosis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The model’s health states used KCCQ-CSS quartiles and death.
Research context only—not evidence of a treatment effect.
- Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.
Health states were defined by Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) quartiles and death.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
PCA helped cluster and classify semaglutide formulation samples under different stress conditions.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
The application of principal component analysis (PCA) enabled the identification of clustering patterns and classification of samples under different stress conditions, while the analysis of loading and contribution line plots allowed recognition of the main spectral features contributing most to the variance.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
MACCE was defined as all-cause mortality, myocardial infarction, heart failure, or stroke combined.
Research context only—not evidence of a treatment effect.
- pubmed-42334436
The primary outcome was incident MACCE, defined as a composite of all-cause mortality, myocardial infarction (MI), HF, or stroke.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this study, a positive ΔCAVI meant arterial stiffness decreased (improved).
Research context only—not evidence of a treatment effect.
- Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes.
ΔCAVI was defined as baseline minus follow-up CAVI. Therefore, a positive ΔCAVI indicates a decrease (i.e., improvement) in arterial stiffness.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study used multivariable regression to find factors linked to information quality.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
Multivariable regression analyses were performed to identify factors associated with information quality.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
The review searched MEDLINE, Embase, and CENTRAL through February 2025.
Research context only—not evidence of a treatment effect.
- Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.
MEDLINE, Embase, and CENTRAL were searched through February 2025.
- Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.
MEDLINE, Embase, and CENTRAL were searched through February 2025.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Hydrophobicity drives GLP-1 analog micelle formation.
Research context only—not evidence of a treatment effect.
- Anisotropic Electrostatics in the Instability of GLP‑1 Analog Micelles: Effects of Electrolytes, Denaturants, pH, and Temperature.
Whereas hydrophobicity drives the micelle formation
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The authors propose a two-hit model: anatomical susceptibility plus sustained hypohydration together trigger NAION.
Research context only—not evidence of a treatment effect.
- pubmed-42547311
We propose a hypothesis-generating 'two-hit' model in which anatomical susceptibility and sustained hypohydration together precipitate NAION.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide was complexed with DOTAP at 1:0–1:18 molar ratios and then loaded into cetyl palmitate SLNs made by microfluidic mixing (herringbone device).
Research context only—not evidence of a treatment effect.
- Microfluidic-assisted formulation of hydrophobic ion pairing-based solid lipid nanoparticles for semaglutide delivery.
Semaglutide was complexed with the cationic lipid DOTAP at different molar ratios (1:0-1:18) and subsequently incorporated into cetyl palmitate-based SLNs produced by microfluidic mixing using a herringbone device.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A hydrophobic ion-pair complex of semaglutide and sodium docusate (SET-DOC) was made.
Research context only—not evidence of a treatment effect.
- pubmed-42349668
we developed a hydrophobic ion pair (HIP) complex of SET and sodium docusate (SET-DOC)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
FTIR, DSC, TGA, and SAXS analyses confirmed formation of the complex and its incorporation into the lipid matrix.
Research context only—not evidence of a treatment effect.
- Microfluidic-assisted formulation of hydrophobic ion pairing-based solid lipid nanoparticles for semaglutide delivery.
FTIR, DSC, TGA and SAXS analyses confirmed the correct formation of the complex and its incorporation into the lipid matrix.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Researchers analyzed semaglutide-related videos on Bilibili and TikTok in a cross-sectional study.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
A cross-sectional content analysis was conducted on semaglutide-related videos from Bilibili and TikTok.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Electrolyte-dependent aggregation of GLP-1 analog micelles is governed by electrostatic interactions.
Research context only—not evidence of a treatment effect.
- Anisotropic Electrostatics in the Instability of GLP‑1 Analog Micelles: Effects of Electrolytes, Denaturants, pH, and Temperature.
electrolyte-dependent aggregation appears to be governed by these electrostatic interactions.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
During adipogenesis, GLP-1 reduced AKT activation.
Research context only—not evidence of a treatment effect.
- pubmed-42425087
Mechanistically, GLP-1 inhibited AKT activation during adipogenesis
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Oral semaglutide delivery is difficult because it is unstable in GI fluids, can be broken down by enzymes, and has limited diffusion through mucus.
Research context only—not evidence of a treatment effect.
- Current trends in semaglutide therapy and strategies to improve its bioavailability.
mucus diffusion limitation
- Current trends in semaglutide therapy and strategies to improve its bioavailability.
degradation through proteolysis by various enzymes
- Current trends in semaglutide therapy and strategies to improve its bioavailability.
Delivery of oral semaglutide becomes difficult due to instability in GI fluids
- Current trends in semaglutide therapy and strategies to improve its bioavailability.
Delivery of oral semaglutide becomes difficult due to instability in GI fluids, degradation through proteolysis by various enzymes, and mucus diffusion limitation;
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Neuroinflammation is described as a core pathological mechanism in PND.
Research context only—not evidence of a treatment effect.
- Semaglutide Alleviates LPS-Induced Cognitive Disorder via O-GlcNAcylation of AKT-mTOR Signaling Pathway Components.
neuroinflammation serving as a core pathological mechanism throughout PND pathogenesis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In BMSCs, GLP-1 reduced fat-cell formation and increased bone-cell formation in a dose-dependent way.
Research context only—not evidence of a treatment effect.
- pubmed-42425087
GLP-1 suppressed adipogenesis and promoted osteogenesis of BMSCs in a dose-dependent manner.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Content validity used I-CVI and S-CVI/Ave, and face validity used agreement with five statements per round.
Research context only—not evidence of a treatment effect.
- pubmed-42602345
Content validity was measured using item-level (I-CVI) and scale-level (S-CVI/Ave) indices, while face validity was assessed by level of agreement to five statements per round.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The authors searched the literature up to May 2026 using semaglutide as a search term.
Research context only—not evidence of a treatment effect.
- Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
A systematic search of PubMed, SciSpace, and Google Scholar was conducted (through May 2026) using terms including GLP1R, GIPR, polymorphisms, pharmacogenomics, semaglutide, tirzepatide, and Italian population.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Nephrology clinicians and community pharmacists rated semaglutide algorithm items on Likert scales to assess content and face validity.
Research context only—not evidence of a treatment effect.
- pubmed-42602345
A two-part questionnaire per algorithm item assessed content and face validity, with nephrology clinicians (nephrologists and kidney pharmacists) and community pharmacists rating items using Likert scales.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Food noise is described as persistent, intrusive thoughts about food that can disrupt daily life.
Research context only—not evidence of a treatment effect.
- Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey.
'Food noise', persistent and intrusive thoughts about food that can disrupt daily life, has emerged as a concern for individuals with obesity, and often impacts quality of life.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide is a GLP-1 receptor agonist.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
Semaglutide, a glucagon-like peptide-1 receptor agonist
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The main outcome measured was change in HbA1c.
Research context only—not evidence of a treatment effect.
- pubmed-42598626
Primary endpoint was the change in HbA1c level.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study analyzed 225 videos: 107 from Bilibili and 118 from TikTok.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
A total of 225 videos were included (107 from Bilibili and 118 from TikTok).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A combined hydrophobic ion pairing and solid lipid nanoparticle approach was explored to improve semaglutide incorporation and delivery-related properties.
Research context only—not evidence of a treatment effect.
- Microfluidic-assisted formulation of hydrophobic ion pairing-based solid lipid nanoparticles for semaglutide delivery.
In the present study, a combined hydrophobic ion pairing (HIP) and solid lipid nanoparticle (SLN) approach was explored to improve semaglutide incorporation and delivery-related properties.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The review says the simplest likely mechanism is that weight loss reduces anatomical load on the airway.
Research context only—not evidence of a treatment effect.
- Incretin-Based Therapies in Obesity-Related Obstructive Sleep Apnea: A Narrative Review of Evidence Tiers and Mechanistic Plausibility.
The most parsimonious mechanistic interpretation is weight-loss-mediated anatomical unloading.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Higher ionic strength screens micelle Coulomb repulsion and promotes aggregation by enabling multipole attractions.
Research context only—not evidence of a treatment effect.
- Anisotropic Electrostatics in the Instability of GLP‑1 Analog Micelles: Effects of Electrolytes, Denaturants, pH, and Temperature.
Increasing ionic strength screens the Coulomb repulsion between micelles, reducing the electrostatic stabilization barrier and allowing orientation-dependent multipole attractions to promote aggregation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The validation included ten nephrology clinicians and 12 community pharmacists.
Research context only—not evidence of a treatment effect.
- pubmed-42602345
Ten nephrology clinicians (five per round for three rounds) and 12 community pharmacists (six per round for two rounds) participated.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide 2.4 mg is a GLP-1 analogue.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
Subcutaneous semaglutide 2.4 mg, a glucagon-like peptide 1 analogue,
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
EQ-5D utility scores were mapped from SF-36 scores using the Rowen et al. (2009) algorithm.
Research context only—not evidence of a treatment effect.
- pubmed-42580587
EuroQol 5-Dimension (EQ-5D) utilities were mapped from Short Form-36 (SF-36) scores using the Rowen et al. (2009) algorithm.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide was complexed with glucosamine and taurolithocholate and put into an n-dodecyl-β-D-maltoside nanomicelle (SGT-M).
Research context only—not evidence of a treatment effect.
- Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.
SEMA was electrostatically complexed with glucosamine and taurolithocholate to enable transporter-mediated recognition, followed by incorporation into an n-dodecyl-β-D-maltoside-based nanomicelle.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A Markov model based on STEP-HFpEF evaluated semaglutide vs placebo for HFpEF with obesity in the German statutory health insurance perspective.
Research context only—not evidence of a treatment effect.
- Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.
We developed a cohort state-transition (Markov) model based on STEP-HFpEF to evaluate semaglutide versus placebo in patients with HFpEF and obesity from the German statutory health insurance (SHI) perspective.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Two independent reviewers scored video quality using GQS, mDISCERN, and JAMA criteria.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
Two independent reviewers evaluated the quality of each video using the Global Quality Scale (GQS), modified DISCERN (mDISCERN), and Journal of the American Medical Association (JAMA) benchmark criteria.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Vascular regenerative cell exhaustion is described as a progressive loss of circulating progenitor cells that help regenerate blood vessels.
Research context only—not evidence of a treatment effect.
- pubmed-42388102
VRCE, the progressive loss of circulating progenitor cells that mediate vessel regeneration, has recently emerged as an underappreciated driver of MACE risk in individuals living with type 2 diabetes (T2D), obesity or atherosclerotic cardiovascular disease.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Two independent reviewers scored videos using GQS, mDISCERN, and JAMA criteria.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
Two independent reviewers evaluated the quality of each video using the Global Quality Scale (GQS), modified DISCERN (mDISCERN), and Journal of the American Medical Association (JAMA) benchmark criteria.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study performed a cross-sectional analysis of semaglutide-related videos on Bilibili and TikTok.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
A cross-sectional content analysis was conducted on semaglutide-related videos from Bilibili and TikTok.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The primary outcomes were changes in HbA1c, body weight, and systolic blood pressure at 6 and 12 months.
Research context only—not evidence of a treatment effect.
- Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response.
Primary outcomes were changes in glycated hemoglobin (HbA1c), body weight, and systolic blood pressure (SBP) at 6 and 12 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
VRCE is described as a progressive loss of circulating progenitor cells that help regenerate blood vessels.
Research context only—not evidence of a treatment effect.
- pubmed-42388102
VRCE, the progressive loss of circulating progenitor cells that mediate vessel regeneration, has recently emerged as an underappreciated driver of MACE risk in individuals living with type 2 diabetes (T2D), obesity or atherosclerotic cardiovascular disease.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Semaglutide improves glycemic control by increasing insulin and decreasing glucagon release in a glucose-dependent way.
Research context only—not evidence of a treatment effect.
- IUPHAR ligand commentary
Semaglutide improves glycemic control by stimulating insulin and lowering glucagon secretion in a glucose-dependent manner [Reference 33890].
- IUPHAR ligand commentary
Semaglutide improves glycemic control by stimulating insulin and lowering glucagon secretion in a glucose-dependent manner [Reference 33890].
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
An electrostatic model using screened monopole-dipole and dipole-dipole attractions and monopole-monopole repulsion was developed.
Research context only—not evidence of a treatment effect.
- Anisotropic Electrostatics in the Instability of GLP‑1 Analog Micelles: Effects of Electrolytes, Denaturants, pH, and Temperature.
An electrostatic model, based on attractive, screened monopole-dipole, dipole-dipole, and repulsive monopole-monopole interactions was developed to interpret results.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Neuroinflammation is described as a core mechanism in PND.
Research context only—not evidence of a treatment effect.
- Semaglutide Alleviates LPS-Induced Cognitive Disorder via O-GlcNAcylation of AKT-mTOR Signaling Pathway Components.
High-risk factors, including advanced age, obesity, diabetes, and preoperative neurological dysfunction, accelerate PND progression, with neuroinflammation serving as a core pathological mechanism throughout PND pathogenesis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
CAVI is a blood pressure-independent measure of arterial stiffness and predicts cardiovascular events.
Research context only—not evidence of a treatment effect.
- Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes.
The cardio-ankle vascular index (CAVI) is a blood pressure-independent marker of arterial stiffness and a well-established predictor of cardiovascular (CV) events.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide was complexed with DOTAP at molar ratios from 1:0 to 1:18.
Research context only—not evidence of a treatment effect.
- Microfluidic-assisted formulation of hydrophobic ion pairing-based solid lipid nanoparticles for semaglutide delivery.
Semaglutide was complexed with the cationic lipid DOTAP at different molar ratios (1:0-1:18)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The videos were collected on February 4, 2026.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
Videos were collected on February 4, 2026.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide can be analyzed using reversed-phase HPLC and LC–MS/MS.
Research context only—not evidence of a treatment effect.
- Analytical methods for the determination of semaglutide in pharmaceutical formulations and biological matrices: A comprehensive review.
Some of these approaches include reversed-phase high-performance liquid chromatography, liquid chromatography/tandem mass spectrometry
- Analytical methods for the determination of semaglutide in pharmaceutical formulations and biological matrices: A comprehensive review.
ultraviolet-visible spectrophotometry, Fourier-transform infrared spectroscopy, Raman spectroscopy
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide was complexed with DOTAP at molar ratios from 1:0 to 1:18 and then incorporated into cetyl palmitate-based solid lipid nanoparticles made by microfluidic mixing with a herringbone device.
Research context only—not evidence of a treatment effect.
- Microfluidic-assisted formulation of hydrophobic ion pairing-based solid lipid nanoparticles for semaglutide delivery.
Semaglutide was complexed with the cationic lipid DOTAP at different molar ratios (1:0-1:18) and subsequently incorporated into cetyl palmitate-based SLNs produced by microfluidic mixing using a herringbone device.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
They used version 26 of the Core Obesity Model (a Markov model) to project outcomes and costs over 40 years.
Research context only—not evidence of a treatment effect.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
The analyses were performed using version 26 of the Core Obesity Model, a Markov state transition model, to project health outcomes and costs at 40 years, based on the evolution of risk factors associated with obesity.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
The analyses were performed using version 26 of the Core Obesity Model, a Markov state transition model, to project health outcomes and costs at 40 years, based on the evolution of risk factors associated with obesity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Anisotropic electrostatic interactions are central to GLP-1 analog micelle instability and aggregation.
Research context only—not evidence of a treatment effect.
- Anisotropic Electrostatics in the Instability of GLP‑1 Analog Micelles: Effects of Electrolytes, Denaturants, pH, and Temperature.
The results here indicate that anisotropic electrostatic interactions play a central role in the instability and aggregation, which appear to arise predominantly from multipole, orientation-dependent electrostatics
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide was complexed with glucosamine and taurolithocholate and put into an n-dodecyl-β-D-maltoside nanomicelle.
Research context only—not evidence of a treatment effect.
- Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.
SEMA was electrostatically complexed with glucosamine and taurolithocholate to enable transporter-mediated recognition, followed by incorporation into an n-dodecyl-β-D-maltoside-based nanomicelle.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
ATR-FTIR spectra detected subtle conformational changes in semaglutide-containing formulations, especially in amide region I linked to secondary structure.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
Spectral data allowed the detection of subtle conformational changes, particularly in the amide region I, which is directly related to the secondary structure.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide-regulated HSPs were screened with transcriptomics and PCR arrays, and co-immunoprecipitation was used to explore how semaglutide increases HSP expression.
Research context only—not evidence of a treatment effect.
- pubmed-42315078
Semaglutide-regulated HSPs were screened by transcriptomics and PCR arrays and co-immunoprecipitation experiments were conducted to explore key factors in semaglutide promoting increased expression of heat shock proteins (HSPs).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this study, a positive ΔCAVI meant arterial stiffness decreased (improved).
Research context only—not evidence of a treatment effect.
- Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes.
Therefore, a positive ΔCAVI indicates a decrease (i.e., improvement) in arterial stiffness.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A combined HIP + SLN approach was tested to improve semaglutide incorporation and delivery-related properties.
Research context only—not evidence of a treatment effect.
- Microfluidic-assisted formulation of hydrophobic ion pairing-based solid lipid nanoparticles for semaglutide delivery.
In the present study, a combined hydrophobic ion pairing (HIP) and solid lipid nanoparticle (SLN) approach was explored to improve semaglutide incorporation and delivery-related properties.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A hydrophobic ion pair complex of semaglutide with sodium docusate (SET-DOC) was developed.
Research context only—not evidence of a treatment effect.
- pubmed-42349668
To address these challenges, we developed a hydrophobic ion pair (HIP) complex of SET and sodium docusate (SET-DOC)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
GLP-1 analog net dipole moment and charge affect attraction and repulsion.
Research context only—not evidence of a treatment effect.
- Anisotropic Electrostatics in the Instability of GLP‑1 Analog Micelles: Effects of Electrolytes, Denaturants, pH, and Temperature.
net dipole moment and charge in GLPA affect attraction and repulsion
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study used multivariable regression to find what factors were linked to information quality.
Research context only—not evidence of a treatment effect.
- Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.
Multivariable regression analyses were performed to identify factors associated with information quality.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Limited epithelial permeability restricts semaglutide’s oral absorption and contributes to exceedingly low oral bioavailability.
Research context only—not evidence of a treatment effect.
- Current trends in semaglutide therapy and strategies to improve its bioavailability.
epithelial permeability restricts the oral absorption of the drug, due to which the oral bioavailability of semaglutide is exceedingly low.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Using PCA on ATR-FTIR data let the researchers cluster and classify samples under different stress conditions for formulations including semaglutide.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
The application of principal component analysis (PCA) enabled the identification of clustering patterns and classification of samples under different stress conditions, while the analysis of loading and contribution line plots allowed recognition of the main spectral features contributing most to the variance.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
They used the first dispensing date as the index date, with a 24-month baseline and 12-month follow-up.
Research context only—not evidence of a treatment effect.
- pubmed-42557547
The first dispensing date served as the index date, establishing a 24-month baseline and a 12-month follow-up period.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study estimated production costs for oral and injectable semaglutide using updated cost-plus pricing methods and 2024-2025 Indian API shipment data, including assumptions about formulation, packaging, tax, and profit.
Research context only—not evidence of a treatment effect.
- How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access.
We applied updated cost-plus pricing methods using 2024-2025 Indian active pharmaceutical ingredient shipment data to estimate production costs for oral and injectable semaglutide, incorporating formulation, packaging, taxation, and profit assumptions.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
ATR-FTIR spectra detected subtle conformational changes, especially in amide region I linked to secondary structure, in semaglutide-containing formulations.
Research context only—not evidence of a treatment effect.
- pubmed-42330703
Spectral data allowed the detection of subtle conformational changes, particularly in the amide region I, which is directly related to the secondary structure.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study aimed to assess real-world cardiometabolic outcomes and predictors of response after starting semaglutide in a tertiary endocrine clinic.
Research context only—not evidence of a treatment effect.
- Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response.
The aim of this study was to evaluate real-world cardiometabolic outcomes and predictors of response following initiation of semaglutide in a tertiary endocrine clinic.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The review says this weight-loss mechanism has not yet been directly confirmed with serial airway imaging, Pcrit measurement, or physiological endotyping in incretin-treated OSA cohorts.
Research context only—not evidence of a treatment effect.
- Incretin-Based Therapies in Obesity-Related Obstructive Sleep Apnea: A Narrative Review of Evidence Tiers and Mechanistic Plausibility.
but it has not yet been directly confirmed by serial upper-airway imaging, Pcrit measurement, or physiological endotyping within incretin-treated OSA cohorts.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Oral semaglutide tablets have limited absorption because semaglutide is hydrophilic and enzymatically unstable in the GI tract.
Research context only—not evidence of a treatment effect.
- pubmed-42349668
oral tablets are more convenient but suffer from limited absorption due to SET's hydrophilicity and enzymatic instability in the gastrointestinal tract.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The optimized SD@SEDDS had a particle size of 85.55 nm.
Research context only—not evidence of a treatment effect.
- pubmed-42349668
with a uniform particle size of 85.55 nm
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide was not detectable in the milk of mothers taking it subcutaneously.
Research context only—not evidence of a treatment effect.
- Semaglutide
Semaglutide was not detectable in the milk of mothers taking the drug subcutaneously.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide was not detectable in milk from mothers taking subcutaneous semaglutide.
Research context only—not evidence of a treatment effect.
- Semaglutide
Semaglutide was not detectable in the milk of mothers taking the drug subcutaneously.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Semaglutide’s reported binding to human serum albumin was 97.8% after 60 mins (ultrafiltration HPLC).
Research context only—not evidence of a treatment effect.
- ChEMBL activities for CHEMBL2108724
Assay: Binding affinity to human serum albumin after 60 mins by ultrafiltration-based HPLC analysis Assay format: single protein format Standard result: PPB = 97.8 %
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Optimized SGT-M had a particle size of 64.7 ± 1.27 nm and near-complete drug incorporation.
Research context only—not evidence of a treatment effect.
- Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.
The optimized SGT-M had a particle size of 64.7 ± 1.27 nm and near-complete drug incorporation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The optimized SGT-M had a particle size of 64.7 ± 1.27 nm.
Research context only—not evidence of a treatment effect.
- Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.
The optimized SGT-M had a particle size of 64.7 ± 1.27 nm
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Oral administration achieved 4.62% relative bioavailability.
Research context only—not evidence of a treatment effect.
- Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.
Oral administration achieved a relative bioavailability of 4.62%.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The formulations fully dissolved in nasal mucus within two hours.
Research context only—not evidence of a treatment effect.
- A microencapsulation strategy for intranasal semaglutide delivery.
The resulting formulations fully dissolved in nasal mucus within two hours, with over 30% absorption occurring in the first 20 minutes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Optimized SD@SEDDS formed a clear emulsion when diluted and had a particle size of 85.55 nm.
Research context only—not evidence of a treatment effect.
- pubmed-42349668
The optimized SD@SEDDS produced a clear emulsion upon dilution, with a uniform particle size of 85.55 nm,
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Optimized SD@SEDDS had drug loading of 2.64 mg/g.
Research context only—not evidence of a treatment effect.
- pubmed-42349668
high drug loading (2.64 mg/g)
- pubmed-42349668
high drug loading (2.64 mg/g),
Safety + tolerability
Risks, organized for scanning.
Injectable semaglutide labels warn about thyroid C-cell tumors observed in rodents; human relevance is unknown. [1]Regulatory labelWegovy prescribing informationCurrent DailyMed label for Wegovy; approved uses, dosing, contraindications, warnings, and adverse reactions.
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Serious hypersensitivity to semaglutide or product excipients
Common effects
- Nausea
- Diarrhea
- Vomiting
Serious risks
- Acute pancreatitis
- Gallbladder disease
- Acute kidney injury from volume depletion
Structured from current product labeling [1]Regulatory labelWegovy prescribing informationCurrent DailyMed label for Wegovy; approved uses, dosing, contraindications, warnings, and adverse reactions.
Products + regulatory context
Same ingredient. Different records.
| Product | Form | Profile scope | Record |
|---|---|---|---|
| Ozempic | Weekly subcutaneous injection | Type 2 diabetes; label includes cardiovascular and kidney risk-reduction claims in specified populations. | [2]Regulatory labelOzempic prescribing informationCurrent DailyMed label for Ozempic; a separate product record from Wegovy and Rybelsus. |
| Wegovy | Weekly injection; current U.S. label also lists a daily tablet presentation | Product- and presentation-specific weight, cardiovascular, and MASH uses. | [1]Regulatory labelWegovy prescribing informationCurrent DailyMed label for Wegovy; approved uses, dosing, contraindications, warnings, and adverse reactions. |
| Rybelsus | Daily oral tablet | Type 2 diabetes; formulation and instructions differ from injectable products. | [13]Published evidence snapshotThese highlights do not include all the information needed to use RYBELSUS®andOZEMPIC®tabletssafely and effectively. See full prescribing information for RYBELSUS andOZEMPICtablets.RYBELSUS (semaglutide) tablets, for oral useOZEMPIC (semaglutide) tablets, for oral useInitial U.S. Approval: 2017dailymed · T1 |
Do not infer dosing, interchangeability, or an approved use from the ingredient name alone. Open the current label for the exact product and presentation.
Administration, interactions + monitoring
The practical clinical context.
- Administration boundary
- Product-specific oral or subcutaneous regimens with gradual titration. The current label and prescriber determine the applicable schedule. [1]Regulatory labelWegovy prescribing informationCurrent DailyMed label for Wegovy; approved uses, dosing, contraindications, warnings, and adverse reactions.
- Monitor
- Watch for persistent severe abdominal symptoms that could indicate pancreatitis and for symptoms of gallbladder disease. [1]Regulatory labelWegovy prescribing informationCurrent DailyMed label for Wegovy; approved uses, dosing, contraindications, warnings, and adverse reactions.
- Monitor
- Monitor glucose when used with insulin or an insulin secretagogue because concomitant therapy can increase hypoglycemia risk. [1]Regulatory labelWegovy prescribing informationCurrent DailyMed label for Wegovy; approved uses, dosing, contraindications, warnings, and adverse reactions.
Research status + gaps
What still needs better answers.
Some extracted findings are not shown because they did not pass Peplexicon's automated evidence checks.
How Peplexicon reads evidence
- Authority
- What kind of source is making the statement?
- Independence
- Do multiple citations represent separate studies—or the same evidence repeated?
- Directness
- Does the population, product, dose, outcome, and time horizon match the claim?
- Consistency
- Do credible sources support, qualify, or contradict one another?
References + discovery
Open the records yourself.
- 1Regulatory labelWegovy prescribing informationOpen ↗
Current DailyMed label for Wegovy; approved uses, dosing, contraindications, warnings, and adverse reactions.
- 2Regulatory labelOzempic prescribing informationOpen ↗
Current DailyMed label for Ozempic; a separate product record from Wegovy and Rybelsus.
- 3Literature indexEvery PubMed result for semaglutideOpen ↗
Live National Library of Medicine literature search; results are not pre-screened or deduplicated.